Ortho Clinical Diagnostics (OCDX) 10-Q 8 Nov 21 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 03, 2021	Oct. 29, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 3, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	OCDX
Entity Registrant Name	Ortho Clinical Diagnostics Holdings plc
Entity Central Index Key	0001828443
Current Fiscal Year End Date	--01-02
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-39956
Entity Tax Identification Number	98-1574150
Entity Address, Address Line One	1001 Route 202
Entity Address, City or Town	Raritan
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08869
City Area Code	908
Local Phone Number	218-8000
Entity Interactive Data Current	Yes
Title of 12(b) Security	Ordinary shares, $0.00001 par value per ordinary share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	X0
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		236,889,470

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Income Statement [Abstract]
Net revenue	$ 522.5	$ 451.1	$ 1,521.8	$ 1,249.6
Cost of revenue, excluding amortization of intangible assets	252.4	234.1	748.7	650.2
Gross profit	270.1	217	773.1	599.4
Selling, marketing and administrative expenses	140.9	121	411	347.9
Research and development expense	32.1	32.7	91.3	82.1
Amortization of intangible assets	33.3	33.1	100.3	98.7
Other operating expense, net	9.8	9.5	27.7	22.8
Income from operations	54	20.7	142.8	47.9
Interest expense, net	36.1	48.9	112.5	148.6
Tax indemnification (income) expense, net	(0.2)	16.5	(0.6)	11.6
Other (income) expense, net	(2.6)	(5.9)	50.8	61.1
Income (loss) before income taxes	20.7	(38.8)	(20)	(173.4)
Provision for (benefit from) income taxes	6	(10.3)	24.4	(2.4)
Net income (loss)	$ 14.7	$ (28.5)	$ (44.4)	$ (171)
Basic net income (loss) per ordinary share	$ 0.06	$ (0.20)	$ (0.20)	$ (1.17)
Basic weighted-average ordinary shares outstanding	235.6	146.4	225.4	146.4
Diluted net income (loss) per ordinary share	$ 0.06	$ (0.20)	$ (0.20)	$ (1.17)
Diluted weighted-average ordinary shares outstanding	242.8	146.4	225.4	146.4

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Net income (loss)	$ 14.7	$ (28.5)	$ (44.4)	$ (171)
Other comprehensive income (loss), before tax:
Foreign currency translation adjustments	(13.9)	8.1	(21.7)	1.7
Other comprehensive income (loss), before tax	(5.9)	5.6	7.5	(49.6)
Income tax provision related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(5.9)	5.6	7.5	(49.6)
Comprehensive income (loss)	8.7	(22.9)	(36.9)	(220.6)
Foreign Currency Derivatives
Other comprehensive income (loss), before tax:
Derivatives	2.1	(3.5)	6.4	(2.3)
Interest Rate Derivatives
Other comprehensive income (loss), before tax:
Derivatives	$ 5.9	$ 1	$ 22.7	$ (49)

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Current assets:
Cash and cash equivalents	$ 255.9	$ 132.8
Accounts receivable (net of allowance for credit losses of $9.7 and $9.8, respectively)	237.8	318.7
Inventories	308.3	278.7
Other current assets	141.8	127
Total current assets	943.8	857.2
Property, plant and equipment, net	782.6	832
Goodwill	570.8	580.1
Intangible assets, net	912.5	1,016.7
Deferred income taxes	7.1	8
Other assets	93	107.5
Total assets	3,309.9	3,401.5
Current liabilities:
Accounts payable	139.3	146.2
Accrued liabilities	251.5	284.7
Deferred revenue	32.6	35.5
Current portion of borrowings	64.4	160
Total current liabilities	487.7	626.4
Long-term borrowings	2,206.9	3,558.5
Employee-related obligations	39.9	39.3
Other liabilities	94.2	120.8
Deferred income taxes	84.4	67.3
Total liabilities	2,913	4,412.3
Commitments and contingencies (Note 15)
Shareholders’ Equity (Deficit):
Preferred redeemable shares, $1.39 nominal value per share, 50,000 and no shares issued and outstanding as of October 3, 2021 and January 3, 2021, respectively	0.1	0
Ordinary shares, $0.00001 par, 1,000,000,000 shares authorized, 236,679,437 and 147,295,511 shares issued and outstanding as of October 3, 2021 and January 3, 2021, respectively	0	0
Additional paid-in capital	2,419.7	975.1
Accumulated deficit	(1,961.9)	(1,917.5)
Accumulated other comprehensive loss	(61)	(68.4)
Total shareholders’ equity (deficit)	396.9	(1,010.8)
Total liabilities and shareholders’ equity (deficit)	$ 3,309.9	$ 3,401.5

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Statement Of Financial Position [Abstract]
Allowance for credit losses	$ 9.7	$ 9.8
Preferred stock, nominal value per share	$ 1.39	$ 1.39
Preferred stock, shares issued	50,000	0
Preferred stock, shares outstanding	50,000	0
Ordinary shares, value per share	$ 0.00001	$ 0.00001
Ordinary shares, shares authorized	1,000,000,000	1,000,000,000
Ordinary shares, shares issued	236,679,437	147,295,511
Ordinary shares, shares outstanding	236,679,437	147,295,511

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($) $ in Millions	Total	Foreign Currency Derivatives	Interest Rate Derivatives	Ordinary Shares	Preferred Redeemable Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive LossForeign Currency Derivatives	Accumulated Other Comprehensive LossInterest Rate Derivatives
Beginning balance at Dec. 29, 2019	$ (812.8)			$ 0	$ 0	$ 964.7	$ (1,705.6)	$ (71.9)
Beginning balance, shares at Dec. 29, 2019				146,437,574	0
Net income (loss)	(171)						(171)
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings				2,831
Exercise of stock options	0.2					0.2
Exercise of stock options, shares				144,161
Recognition of stock-based compensation	6.2					6.2
Derivatives, net of tax of $0.0		$ (2.3)	$ (49)						$ (2.3)	$ (49)
Foreign currency translation adjustments	1.7							1.7
Ending balance at Sep. 27, 2020	(1,027)			$ 0	$ 0	971.1	(1,876.6)	(121.5)
Ending balance, shares at Sep. 27, 2020				146,584,566	0
Beginning balance at Jun. 28, 2020	(1,006.5)			$ 0	$ 0	968.7	(1,848.1)	(127.1)
Beginning balance, shares at Jun. 28, 2020				146,560,341	0
Net income (loss)	(28.5)						(28.5)
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings				2,831
Exercise of stock options, shares				21,394
Recognition of stock-based compensation	2.4					2.4
Derivatives, net of tax of $0.0		(3.5)	1						(3.5)	1
Foreign currency translation adjustments	8.1							8.1
Ending balance at Sep. 27, 2020	(1,027)			$ 0	$ 0	971.1	(1,876.6)	(121.5)
Ending balance, shares at Sep. 27, 2020				146,584,566	0
Beginning balance at Jan. 03, 2021	(1,010.8)			$ 0	$ 0	975.1	(1,917.5)	(68.4)
Beginning balance, shares at Jan. 03, 2021				147,295,511	0
Net income (loss)	(44.4)						(44.4)
Restricted Stock, Shares Vested Net of Shares for Tax Withholdings				321,653
Issuance of ordinary shares upon completion of initial public offering, net of commissions, underwriting discounts and offering costs	1,415.2					1,415.2
Issuance of ordinary shares upon completion of initial public offering, net of commissions, underwriting discounts and offering costs, shares				87,400,000
Issuance of incorporation shares consisting of ordinary share and preferred redeemable shares	0.1				$ 0.1
Issuance of incorporation shares consisting of ordinary shares and preferred redeemable shares, shares				1	50,000
Exercise of stock options	9.9					9.9
Exercise of stock options, shares				1,662,272
Recognition of stock-based compensation	19.6					19.6
Derivatives, net of tax of $0.0		6.4	22.7						6.4	22.7
Foreign currency translation adjustments	(21.7)							(21.7)
Ending balance at Oct. 03, 2021	396.9			$ 0	$ 0.1	2,419.7	(1,961.9)	(61)
Ending balance, shares at Oct. 03, 2021				236,679,437	50,000
Beginning balance at Jul. 04, 2021	375.6			$ 0	$ 0.1	2,407	(1,976.6)	(54.9)
Beginning balance, shares at Jul. 04, 2021				234,921,002	50,000
Net income (loss)	14.7						14.7
Restricted Stock, Shares Vested Net of Shares for Tax Withholdings				321,653
Exercise of stock options	7.6					7.6
Exercise of stock options, shares				1,436,782
Recognition of stock-based compensation	5.1					5.1
Derivatives, net of tax of $0.0		$ 2.1	$ 5.9						$ 2.1	$ 5.9
Foreign currency translation adjustments	(13.9)							(13.9)
Ending balance at Oct. 03, 2021	$ 396.9			$ 0	$ 0.1	$ 2,419.7	$ (1,961.9)	$ (61)
Ending balance, shares at Oct. 03, 2021				236,679,437	50,000

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Foreign Currency Derivatives
Derivatives, tax	$ 0	$ 0	$ 0	$ 0
Interest Rate Derivatives
Derivatives, tax	$ 0	$ 0	$ 0	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020
Cash Flows from Operating Activities:
Net loss	$ (44.4)	$ (171)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation and amortization	246.6	239.6
Unrealized foreign exchange (gains) losses, net	(18.2)	51.1
Loss on extinguishment of debt	50.3	12.6
Amortization of deferred financing costs and original issue discount	6.5	8
Stock-based compensation	19.6	6.2
Deferred tax provision	18.6	4.3
Change in allowance for credit losses	1.2	1.4
Other, net	(9.7)	1.4
Changes in operating assets and liabilities:
Accounts receivable	73.7	34.5
Inventories	(117.3)	(126.9)
Other current and non-current assets	(14.4)	(27.6)
Accounts payable and accrued liabilities	(28.9)	(75.8)
Deferred revenue	(2.7)	(9.3)
Other current and non-current liabilities	7.3	2.9
Cash provided by (used in) operating activities	188.2	(48.6)
Cash Flows from Investing Activities:
Purchases of property, plant and equipment	(27.2)	(28.4)
Proceeds from cross currency swaps	15.2	2.7
Milestone payments and other, net	0.2	(1.8)
Cash used in investing activities	(11.7)	(27.5)
Cash Flows from Financing Activities:
Proceeds from initial public offering	1,426.4	0
Payment of initial public offering costs	(9.2)	0
Proceeds from long-term borrowings	0	1,421
Payments on long-term borrowings	(1,407.9)	(1,347.7)
Payments on short-term borrowings, net	(81.1)	(2.2)
Proceeds from exercise of stock options	9.9	0.2
Cash (used in) provided by financing activities	(61.9)	71.3
Effect of exchange rate changes on cash	(1)	0.5
Increase (decrease) in cash, cash equivalents and restricted cash	113.5	(4.3)
Cash, cash equivalents and restricted cash at beginning of period	144.2	84
Cash, cash equivalents and restricted cash at end of period	$ 257.7	$ 79.7

General and Description of the

General and Description of the Business	9 Months Ended
	Oct. 03, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General and Description of the Business	(1) General and description of the business Ortho Clinical Diagnostics Holdings plc (“UK Holdco”), formerly known as Ortho-Clinical Diagnostics Bermuda Co. Ltd. (“Bermuda Holdco”), is a public limited company incorporated under the laws of England and Wales. UK Holdco became the new holding company of Bermuda Holdco and its subsidiaries and upon incorporation, UK Holdco had an initial share capital of one ordinary share and 50,000 preferred redeemable shares (“Incorporation Shares”). On January 25, 2021, The Carlyle Group L.P. (“Carlyle”), and all other shareholders of Bermuda Holdco contributed all of their outstanding equity interests in Bermuda Holdco to UK Holdco in exchange for ordinary shares of UK Holdco on a 1-for-1 basis (“Reorganization Transactions”). UK Holdco is a holding company with no business operations or assets other than cash, intercompany receivables, miscellaneous administrative costs and guarantees of certain obligations of Ortho-Clinical Diagnostics, Inc. (“Ortho U.S.”) and 100 % of its ownership interest of Ortho-Clinical Diagnostics Holdings Luxembourg S.à r.l., which itself is a holding company with no operations or assets other than cash, intercompany receivables, miscellaneous administrative costs and its ownership of 100 % of the capital stock of Ortho-Clinical Diagnostics S.A. (“LuxCo”). LuxCo, together with its indirect wholly owned subsidiary, Ortho U.S., are co-borrowers under the Senior Secured Credit Facilities and co-issuers of the Notes (each as defined in Note 7). UK Holdco’s global operations are conducted by indirect wholly owned subsidiaries. The terms “we”, “us”, “our”, “its”, and the “Company” refer to UK Holdco and its consolidated subsidiaries after giving effect to the Reorganization Transactions. The Company is a leading global provider of in-vitro diagnostics (“IVD”) solutions to the clinical laboratory and transfusion medicine communities. The Company maintains a commercial presence in more than 130 countries and territories. The Company’s instruments, assays, reagents and other consumables are used in hospitals, laboratories, clinics, blood banks and donor centers worldwide. The Company is globally operated with manufacturing facilities in the United States (“U.S.”) and the United Kingdom (“U.K.”) and with sales centers, administrative offices and warehouses located throughout the world. Both the Company’s domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. The Company has a direct commercial presence in more than 30 countries, including many of the regions most impacted by the COVID-19 pandemic. A decrease in shipments to the Company’s customers began to occur during the fiscal quarter ended June 28, 2020 in many countries, including the U.S. As a result, during the fiscal year ended January 3, 2021, the Company experienced decreased revenues and incurred idle or underutilized facilities costs, higher freight and higher distribution costs compared to the periods prior to the pandemic. During the fiscal quarter ended January 3, 2021, the Company started to experience a recovery in the base business of its core revenue, which continued through the fiscal nine months ended October 3, 2021. During the same period, the Company also continued to experience higher distribution costs due to higher shipping rates as a result of the COVID-19 pandemic. During the fiscal quarter ended April 4, 2021, the Company completed its initial public offering (“IPO”) of ordinary shares at a price of $ 17.00 per share. The Company issued and sold 87,400,000 ordinary shares in the IPO, including 11,400,000 ordinary shares issued pursuant to the full exercise of the underwriters’ option to purchase additional shares. The ordinary shares sold in the IPO were registered under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to a Registration Statement on Form S-1, which was declared effective by the Securities and Exchange Commission (“SEC”) on January 29, 2021. The offering generated net proceeds of $ 1,426.4 million after deducting underwriting discounts and commissions. The Company used a portion of the net proceeds from the IPO (i) to redeem $ 160.0 million of its 2025 Notes (as defined in Note 7), plus accrued interest thereon and $ 11.8 million of redemption premium, (ii) to redeem $ 270.0 million of its 2028 Notes (as defined in Note 7), plus accrued interest thereon and $ 19.6 million of redemption premium, (iii) to repay $ 892.7 million in aggregate principal amount of borrowings under its Dollar Term Loan Facility (as defined in Note 7) and (iv) for working capital and general corporate purposes. In September 2021, the Company completed an underwritten secondary offering (the “Secondary Offering” ) of 25.3 million ordinary shares held by a selling shareholder affiliated with Carlyle, including 3.3 million ordinary shares pursuant to the full exercise of the underwriters’ option to purchase additional shares. The ordinary shares sold in the Secondary Offering were registered under the Securities Act pursuant to a Registration Statement on Form S-1, which was declared effective by the SEC on September 9, 2021. The Company did not offer any ordinary shares in this transaction and did not receive any proceeds from the sale of the ordinary shares by the selling shareholder. The Company incurred costs of $ 1.1 million in relation to the Secondary Offering for the three and nine months ended October 3, 2021, which were recorded in selling, marketing and administrative expenses in the unaudited consolidated statement of operations. These unaudited consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. As shown in the unaudited consolidated financial statements, the Company has total Cash and cash equivalents of $ 255.9 million and an Accumulated deficit of $ 1,961.9 million as of October 3, 2021. The Company reported a Net loss of $ 44.4 million and Cash provided by operating activities of $ 188.2 million during the fiscal nine months ended October 3, 2021. The Company’s primary future cash needs will be to meet debt service requirements, working capital needs and capital expenditures. Management is required to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued and, if so, disclose that fact. The Company’s debt agreements contain various covenants that may restrict the Company’s ability to borrow on available credit facilities and future financing arrangements and require the Company to remain below a specific credit coverage threshold. The Company’s Credit Agreement (as defined in Note 7) has a financial covenant referred to as the First Lien Net Leverage Ratio, (as defined in the Credit Agreement, not to exceed 5.5 -to-1, subject to a 50 basis point step-down on September 30, 2022) that is tested when borrowings and letters of credit issued under the Revolving Credit Facility (as defined in Note 7) exceed 30 % of the committed amount at any period end reporting date. Under the terms of the Credit Agreement, during the fiscal quarter ended July 4, 2021, the Company achieved a 50 basis point step-down on the interest rate on its Senior Secured Credit Facilities (as defined in Note 7) as a result of meeting its First Lien Net Leverage Ratio targets. As of October 3, 2021 , the Company had no outstanding borrowings under its Revolving Credit Facility and letters of credit issued under the Revolving Credit Facility totaled $ 45.0 million. As of October 3, 2021, the Company was in compliance with the financial covenant. In the event the Company does not comply with the financial covenant of the Revolving Credit Facility, the lenders will have the right to call on all of the borrowings under the Revolving Credit Facility. If the lenders on the Revolving Credit Facility terminate their commitments and accelerate the loans, this would become a cross default to other material indebtedness. The Company evaluated its liquidity position and ability to comply with financial covenants in its Revolving Credit Facility as of the date of the issuance of these unaudited consolidated financial statements. Based on this evaluation, management believes that the Company’s financial position, Cash provided by operating activities combined with Cash and cash equivalents, and borrowing capacity available under its Revolving Credit Facility, will be sufficient to fund its current obligations, capital spending, debt service requirements and working capital requirements for a period of at least the next 12 months from the issuance of these unaudited consolidated financial statements. Should it become necessary, the Company may seek to raise additional capital within the next 12 months through borrowings on credit facilities, other financing activities and/or the public or private sale of equity securities. The Company may also need to control discretionary spending, which could impact its planned general and administrative, research and development, or capital spend in an effort to provide sufficient funds to continue its operations or maintain compliance with the financial covenants, and the Company may be subject to adverse business conditions due to the global COVID-19 pandemic, all of which could adversely affect the Company’s business.

Basis of Presentation of the Un

Basis of Presentation of the Unaudited Consolidated Financial Statements	9 Months Ended
	Oct. 03, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation of the Unaudited Consolidated Financial Statements	(2) Basis of presentation of the unaudited consolidated financial statements These unaudited consolidated financial statements for the Company include the accounts of UK Holdco and its subsidiaries. All intercompany accounts and transactions have been eliminated. These unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and Regulation S-X. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation have been included. Results for the fiscal quarter and nine months ended October 3, 2021 should not be considered indicative of results for the fiscal year ending January 2, 2022. These unaudited consolidated financial statements do not represent complete financial statements and should be read in conjunction with the Company’s audited consolidated financial statements and footnotes thereto for the fiscal year ended January 3, 2021 in the Company’s most recent Annual Report on Form 10-K. The Company follows the concept of a fiscal year which ends on the Sunday nearest to the end of the month of December, and fiscal quarters which end on the Sunday nearest to the end of the months of March, June, and September. Each fiscal quarter presented in this Quarterly Report on Form 10-Q consists of 13 weeks. Amounts reported in millions have been calculated based on underlying, unrounded amounts. Amounts presented in tables may not total due to rounding. Percentages have been calculated using underlying, unrounded amounts. Stock Split On January 18, 2021, the Company approved an issuance of 54,860,691 shares, or an additional 0.5934 share for each existing share, which effected a 1.5934 -for-1 stock split of its ordinary shares. All references to share and per share amounts in the Company’s unaudited consolidated financial statements have been retrospectively revised to reflect the stock split.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Oct. 03, 2021
Accounting Policies [Abstract]
Recent Accounting Pronouncements	(3) Recent accounting pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which enhances and simplifies various aspects of the income tax accounting guidance related to intra period tax allocations, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting. The Company adopted this guidance on January 4, 2021 and the adoption did not have a material impact on the Company’s unaudited consolidated financial statements. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope , which clarifies that certain optional expedients and exceptions in Topic 848 apply to derivative instruments that use an interest rate for margining, discounting, or contract price alignment that is modified as a result of reference rate reform. The guidance in ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. The optional amendments can be applied on a full retrospective basis as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent to the date of the issuance of a final update, up to the date that financial statements are available to be issued. The guidance is not currently applicable to the Company. In a future period, the Company may apply elections and evaluate the impact of adoption, as applicable. In July 2021, the FASB issued ASU 2021-05, Leases (Topic 842): Lessors – Certain Leases with Variable Lease Payments, which amends the accounting for lease contracts that have variable lease payments that do not depend on a reference index or rate, and which would have resulted in the recognition of a loss at lease commencement if classified as a sales-type or direct financing lease. Upon adoption, lessors will classify and account for leases with variable payments that do not depend on a reference index or rate as an operating lease if the lease would have been classified as a sales-type or direct financing lease, and if the lessor would have otherwise recognized a loss at lease commencement. The guidance in ASU 2021-05 is effective for fiscal years beginning after December 15, 2021 and can be applied either prospectively or retrospectively for reporting entities that have adopted Topic 842 prior to the issuance date of this amendment. The Company is currently evaluating the impact that adoption of this guidance will have on its consolidated financial statements.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Oct. 03, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	(4) Net income (loss) per share Basic net income (loss) per ordinary share is based on the weighted-average number of ordinary shares outstanding during the period. Diluted net income (loss) per ordinary share is based on the weighted-average number of ordinary shares and ordinary share equivalents, calculated using the treasury stock method, outstanding during the period. The Company excludes potential ordinary share equivalents from the calculation if the effect would be anti-dilutive. For each period specified below, the Company incurred a Net loss, except for fiscal quarter ended October 3, 2021, in which the Company reported Net income. For the periods in which the Company incurred a Net loss, it excluded potential ordinary share equivalents from the calculations of Diluted net loss per ordinary share because the effect was anti-dilutive. The weighted-average number of ordinary shares used in the computation of basic and diluted net income (loss) per share were as follows: Fiscal Quarter Ended Fiscal Nine Months Ended (In millions) October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Basic weighted-average ordinary shares outstanding 235.6 146.4 225.4 146.4 Effect of stock options, unvested restricted shares and 7.2 — — — Diluted weighted-average ordinary shares 242.8 146.4 225.4 146.4 The following table provides the total outstanding ordinary share equivalents, unaffected by the treasury stock method weighted-average calculation, as of the end of each period below: Fiscal Quarter Ended Fiscal Nine Months Ended (In millions) October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Stock options 13.9 16.2 13.9 16.2 Unvested restricted shares and restricted stock 0.6 0.3 0.6 0.3 14.5 16.5 14.5 16.5

Revenue

Revenue	9 Months Ended
	Oct. 03, 2021
Revenue From Contract With Customer [Abstract]
Revenue	(5) Revenue Contract balances Timing of revenue recognition may differ from timing of invoicing to customers. The Company records an asset when revenue is recognized prior to invoicing a customer (“contract asset”). Contract assets are included within Other current assets or Other assets in the Company’s unaudited consolidated balance sheet and are transferred to accounts receivable when the right to payment becomes unconditional. The balance of Contract assets recorded in the Company’s consolidated balance sheets were as follows: October 3, 2021 January 3, 2021 Other current assets $ 47.8 $ 40.4 Other assets 0.8 2.4 Total contract assets $ 48.7 $ 42.8 The contract asset balance consists of the following components:  A customer supply agreement under which the difference between the timing of invoicing and revenue recognition resulted in a contract asset of $ 12.7 million and $ 15.1 million as of October 3, 2021 and January 3, 2021, respectively, of which $ 0.8 million and $ 2.4 million were recorded in Other assets as of October 3, 2021 and January 3, 2021 respectively.  Contractual arrangements with certain customers under which the Company invoices the customers based on reportable results generated by its reagents; however, control of the goods transfers to the customers upon shipment or delivery of the products, as determined under the terms of the contract. Using the expected value method, the Company estimates the number of reagents that will generate a reportable result. The Company records the revenue upon shipment and an associated contract asset, and relieves the contract asset upon completion of the invoicing. The balance of the contract asset related to these arrangements was $ 36.0 million and $ 24.3 million as of October 3, 2021 and January 3, 2021, respectively.  One of the Company’s contract manufacturing agreements that recognizes revenue as the products are manufactured. The balance of the contract asset related to this arrangement was immaterial as of October 3, 2021 and $ 3.4 million as of January 3, 2021. The Company reviews contract assets for expected credit losses resulting from the collectability of customer accounts. Expected losses are established based on historical losses, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts. No credit losses related to contract assets were recognized during the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020, respectively. The Company recognizes a contract liability when a customer pays an invoice prior to the Company transferring control of the goods or services (“contract liabilities”). The Company’s contract liabilities consist of deferred revenue primarily related to customer service contracts. The Company classifies deferred revenue as current or noncurrent based on the timing of the transfer of control or performance of the service. The balance of the Company’s current deferred revenue was $ 32.6 million and $ 35.5 million as of October 3, 2021 and January 3, 2021, respectively. The Company has one arrangement with a customer where the revenue is expected to be recognized beyond one year. The balance of the deferred revenue included in long-term liabilities was $ 5.8 million and $ 6.6 million as of October 3, 2021 and January 3, 2021, respectively, and was included in Other liabilities in the unaudited consolidated balance sheets. The amount of deferred revenue as of January 3, 2021 that was recorded in Net revenue during the fiscal nine months ended October 3, 2021 was $ 31.3 million. Disaggregation of revenue The Company generates product revenue in the following lines of business:  Clinical Laboratories—Focused on clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a broad spectrum of therapeutic areas.  Transfusion Medicine—Focused on (i) immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions, and (ii) donor screening instruments and tests used for blood and plasma screening for infectious diseases for customers primarily in the United States.  Other Product Revenue—Includes revenues primarily from contract manufacturing. The Company also enters into collaboration and license agreements pursuant to which the Company derives collaboration and royalty revenues. During the fiscal quarter ended October 3, 2021, the Company received an award of $ 8.5 million in connection with an arbitration proceeding related to one of its collaboration agreements, which was recorded in Net revenue. During the fiscal quarter ended September 27, 2020, the Company entered into two agreements with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services (“HHS”), for two awards of up to $ 13.6 million to develop and submit Emergency Use Authorizations and 510(k) applications to the U.S. Food and Drug Administration (“FDA”) for its COVID-19 antigen and antibody tests, respectively. An additional award was granted to the Company on April 16, 2021 for an amount up to $ 3.6 million to submit a 510(k) application for its COVID-19 antigen test. During the fiscal quarter and nine months ended October 3, 2021 , the Company recognized $ 1.5 million and $ 7.3 million, respectively, of Net revenue related to these grants based upon project milestones completed to date. During both the fiscal quarter and nine months ended September 27, 2020, the Company recognized $ 2.5 million of Net revenue related to these grants. The following table summarizes Net revenue by line of business for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Clinical Laboratories $ 336.6 $ 300.1 $ 993.9 $ 816.7 Transfusion Medicine 170.7 140.6 494.5 414.5 Other Product Revenue — 3.3 5.6 3.7 Total Product Revenue 507.4 444.1 1,494.1 1,234.9 Collaborations and Other Revenue 15.1 7.0 27.8 14.7 Net Revenue $ 522.5 $ 451.1 $ 1,521.8 $ 1,249.6

Inventories

Inventories	9 Months Ended
	Oct. 03, 2021
Inventory Disclosure [Abstract]
Inventories	(6) Inventories The Company’s inventories were as follows: October 3, 2021 January 3, 2021 Raw materials and supplies $ 71.5 $ 77.2 Goods in process 38.3 35.2 Finished goods 198.6 166.3 Total Inventories $ 308.3 $ 278.7

Borrowings and Other Arrangemen

Borrowings and Other Arrangements	9 Months Ended
	Oct. 03, 2021
Debt Disclosure [Abstract]
Borrowings and Other Arrangements	(7) Borrowings and other arrangements As of October 3, 2021 and January 3, 2021, the components of borrowings were as follows: October 3, 2021 January 3, 2021 Senior Secured Credit Facilities Dollar Term Loan Facility $ 1,292.8 $ 2,185.5 Euro Term Loan Facility 357.2 408.9 Revolving Credit Facility — — 2028 Notes 405.0 675.0 2025 Notes 240.0 400.0 Accounts Receivable Financing — 75.0 Sale and Leaseback Financing — 20.5 Finance lease obligation 0.8 1.0 Other short-term borrowings 0.8 0.9 Other long-term borrowings 2.9 3.9 Unamortized deferred financing costs ( 22.6 ) ( 40.9 ) Unamortized original issue discount ( 5.6 ) ( 11.3 ) Total borrowings 2,271.3 3,718.5 Less: Current portion ( 64.4 ) ( 160.0 ) Long-term borrowings $ 2,206.9 $ 3,558.5 Senior secured credit facilities On February 5, 2021, the Company entered into a fifth amendment of its credit agreement (as amended, the “Credit Agreement”) governing its senior secured credit facilities, which consist of (i) the Dollar Term Loan Facility, (ii) the euro-denominated senior secured term loan facility in an amount equal to € 337.4 million (the “Euro Term Loan Facility” and, together with the Dollar Term Loan Facility, the “Term Loan Facilities”), and (iii) the multi-currency senior secured revolving facility with commitments of $ 500.0 million (the “Revolving Credit Facility”) (collectively, the “Senior Secured Credit Facilities”), which increased the Revolving Credit Facility contained in the credit agreement by $ 150.0 million to an aggregate amount of $ 500.0 million and extended the maturity date to February 5, 2026 , provided that such date may be accelerated subject to certain circumstances as set forth in the fifth amendment. To the extent that the aggregate principal amount of the Dollar Term Loan Facility and Euro Term Loan Facility (and any Refinancing Indebtedness (as defined in the Credit Agreement) with respect thereto that matures on or prior to June 30, 2025) outstanding as of March 31, 2025 exceeds $ 500.0 million then the maturity date with respect to the Revolving Credit Facility shall be March 31, 2025. All other terms of the Senior Secured Credit Facilities will remain substantially the same except as otherwise amended by the fifth amendment. In February 2021, the Company used a portion of the proceeds from its IPO to repay $ 892.7 million of borrowings under the Dollar Term Loan Facility and recognized a loss on early extinguishment of debt of $ 11.4 million, which is recorded as a component of Other expense, net during the fiscal nine months ended October 3, 2021. As of October 3, 2021 , there was no outstanding balance under the Revolving Credit Facility and letters of credit issued under the Revolving Credit Facility totaled $ 45.0 million, which reduced the availability under the Revolving Credit Facility to $ 455.0 million. The Senior Secured Credit Facilities are subject to various covenants that may restrict the Company’s ability to borrow on available credit facilities and future financing arrangements or require the Company to remain below a specific credit coverage threshold as indicated in our debt agreements. The Senior Secured Credit Facilities include a financial covenant that is tested when borrowings and letters of credit issued under the Revolving Credit Facility exceed 30 % of the committed amount at any period end reporting date and provides that LuxCo will not permit the First Lien Net Leverage Ratio as of the end of such fiscal quarter of the LuxCo and its Restricted Subsidiaries (as defined in the Credit Agreement) to be greater than (i) 5.50 :1.00 for each fiscal quarter ending on or prior to September 30, 2022 and (ii) 5.00 :1:00 for each fiscal quarter ending thereafter. Under the terms of the Credit Agreement, during the fiscal quarter ended July 4, 2021, the Company achieved a 50 basis point step-down on the interest rate on its Senior Secured Credit Facilities as a result of meeting its First Lien Net Leverage Ratio targets. The Company was in compliance with the covenants as of October 3, 2021. As of October 3, 2021 and January 3, 2021, the remaining balance of deferred financing costs related to the Dollar Term Loan Facility was $ 8.6 million and $ 17.3 million, respectively. As of October 3, 2021 and January 3, 2021, the remaining balance of deferred financing costs related to the Euro Term Loan Facility was $ 3.8 million and $ 4.6 million, respectively. As of October 3, 2021 and January 3, 2021, the remaining unamortized balance related to the Revolving Credit Facility was $ 3.1 million and $ 3.4 million, respectively. The effective interest rate of the Dollar Term Loan Facility and Euro Term Loan Facility as of October 3, 2021 is 5.76 % and 3.88 %, respectively. 2025 Notes On June 11, 2020, the LuxCo and Ortho U.S. (collectively, the “Issuers”), issued $ 400.0 million aggregate principal amount of 7.375 % Senior Notes due 2025 (the “2025 Notes’), on which interest is payable semi-annually in arrears on June 1 and December 1 of each year. The 2025 Notes will mature on June 1, 2025 . The 2025 Notes and guarantees thereof are senior unsecured obligations and rank equally in right of payment with all of the Issuers’ and guarantors’ existing and future senior debt, including the 2028 Notes (as defined below). The 2025 Notes and the guarantees thereof are effectively subordinated to any of the Issuers’ and guarantors’ existing and future secured debt, including the Senior Secured Credit Facilities, to the extent of the value of the assets securing such debt. In addition, the 2025 Notes and the guarantees thereof rank senior in right of payment to all of the Issuers’ and guarantors’ future subordinated debt and will be structurally subordinated to the liabilities of the Issuers’ non-guarantor subsidiaries. The Company incurred deferred financing costs of $ 7.5 million related to the 2025 Notes, which were capitalized as deferred financing costs and are being amortized using the effective interest method as a component of interest expense over the life of the 2025 Notes. On or after June 1, 2022 , the Issuers have the option to redeem all or part of the 2025 Notes at the following redemption prices (expressed as percentages of principal amount): Year Price 2022 103.688 % 2023 101.844 % 2024 and thereafter 100.000 % Notwithstanding the foregoing, at any time and from time to time prior to June 1, 2022, the Issuers may at their option redeem in the aggregate up to 100 % of the original aggregate principal amount of the 2025 Notes plus accrued and unpaid interest, if any to, but not including, the date of redemption, plus a “make-whole premium.” The Issuers may also, at their option, redeem up to 40 % of the principal amount of the 2025 Notes with the net cash proceeds of certain equity offerings at a redemption price of 107.375 % of the principal amount of the 2025 Notes redeemed, plus accrued and unpaid interest, if any, to, but not including, the date of redemption. On February 5, 2021, the Company used a portion of the proceeds from its IPO to redeem $ 160.0 million aggregate principal amount of the 2025 Notes, plus accrued interest thereon and $ 11.8 million of redemption premium, which was recorded as a component of Other expense, net, during the fiscal nine months ended October 3, 2021. The redemption resulted in an extinguishment loss recognized of $ 14.5 million, which consisted of $ 2.7 million of unamortized deferred issuance costs and $ 11.8 million of the redemption premium. As of October 3, 2021 and January 3, 2021, the remaining unamortized balance of deferred issuance costs was $ 3.6 million and $ 7.0 million, respectively. The effective interest rate on the 2025 Notes is 8.03 %. 2028 Notes On January 27, 2020, the Issuers, issued $ 675.0 million aggregate principal amount of 7.250 % Senior Notes due 2028 (the “2028 Notes” and together with the 2025 Notes, the “Notes”), on which interest is payable semi-annually in arrears on February 1 and August 1 of each year. The 2028 Notes will mature on February 1, 2028 . The 2028 Notes and the guarantees thereof are senior unsecured obligations and rank equally in right of payment with all of the Issuers’ and guarantors’ existing and future senior debt, including the 2025 Notes. The 2028 Notes and the guarantees thereof are effectively subordinated to any of the Issuers’ and guarantors’ existing and future secured debt, including the Senior Secured Credit Facilities, to the extent of the value of the assets securing such debt. In addition, the 2028 Notes and the guarantees thereof rank senior in right of payment to all of the Issuers’ and guarantors’ future subordinated debt and will be structurally subordinated to the liabilities of the Issuers’ non-guarantor subsidiaries. The Company incurred deferred financing costs of $ 12.9 million related to the 2028 Notes, which were capitalized as deferred financing costs and are being amortized using the effective interest method as a component of interest expense over the life of the 2028 Notes. On or after February 1, 2023 , the Issuers have the option to redeem all or part of the 2028 Notes at the following redemption prices (expressed as percentages of principal amount): Year Price 2023 103.625 % 2024 101.813 % 2025 and thereafter 100.000 % Notwithstanding the foregoing, at any time and from time to time prior to February 1, 2023, the Issuers may at their option redeem in the aggregate up to 100 % of the original aggregate principal amount of the 2028 Notes plus accrued and unpaid interest, if any to, but not including, the date of redemption, plus a “make-whole premium.” The Issuers may also, at their option, redeem up to 40 % of the principal amount of the 2028 Notes with the net cash proceeds of certain equity offerings at a redemption price of 107.25 % of the principal amount of the 2028 Notes redeemed, plus accrued and unpaid interest, if any, to, but not including, the date of redemption. On February 5, 2021, the Company used a portion of the proceeds from its IPO to redeem $ 270.0 million aggregate principal amount of the 2028 Notes, plus accrued interest thereon and $ 19.6 million of redemption premium. The redemption resulted in an extinguishment loss recognized of $ 24.3 million, which consisted of $ 4.7 million of unamortized deferred issuance costs and $ 19.6 million of the redemption premium, which is recorded as a component of Other expense, net during the fiscal nine months ended October 3, 2021. As of October 3, 2021 and January 3, 2021, the remaining unamortized balance of deferred issuance costs was $ 6.6 million and $ 11.8 million, respectively. The effective interest rate on the 2028 Notes is 7.76 %. 2022 Notes On January 28, 2020, the Company used the net proceeds from the issuance of the Euro Term Loan Facility and 2028 Notes, after payment of fees and expenses, to fund the redemption and discharge of $ 1.0 billion of the $ 1.3 billion in aggregate principal amount of 6.625 % Senior Notes due 2022 (the “2022 Notes”). On June 12, 2020 the Company used the net proceeds from the issuance of the 2025 Notes, after payments of fees and expenses, to fund the redemption and discharge of the remaining $ 300.0 million of the 2022 Notes. The redemption of the 2022 Notes was accounted for as an extinguishment of debt. During the fiscal nine months ended September 27, 2020, the Company recorded a $ 12.6 million loss on extinguishment of debt, primarily related to the unamortized deferred financings costs on the redeemed 2022 Notes, included as a component of Other expense, net. Sale and leaseback financing In June 2016, the Company entered into a sale-leaseback financing arrangement with a third-party financing company (the “Buyer-lessor”) related to specific property and equipment of the Company. The property and equipment were sold for $ 36.3 million and leased back over an initial term of two years . The monthly lease payments were $ 1.5 million until the equipment is repurchased or the lease is terminated. At the end of the initial term, the Company could repurchase the property and equipment at a price to be negotiated with the Buyer-lessor or terminate the lease arrangement, return the property or (possibly) enter into a new lease agreement. During the fiscal quarter ended July 1, 2018, the Company gave notice to the Buyer-lessor that it intends to negotiate with the Buyer-lessor the purchase of the property and equipment at the end of the initial term and have had discussions on negotiating the repurchase price for the property and equipment. Pursuant to the sale-leaseback financing agreement, if the parties do not reach a new lease agreement to purchase the property and equipment at the end of the initial term, the lease will automatically renew for another year, and afterwards, the lease will automatically be renewed for successive six month periods, provided that each of the Company and the Buyer-lessor have a right to terminate the lease agreement 30 days prior to the end of each six month renewal period. A security deposit for the leaseback was retained by the third-party financing company, the balance of which was $ 9.1 million as of January 3, 2021 and was included in Other current assets in the consolidated balance sheet. The transaction did not meet the criteria for sale-leaseback accounting as the security deposit constitutes a continuing involvement. Therefore, the Company accounted for this arrangement as a financing over 42 months and recorded a financing obligation amounting to $ 36.3 million at inception. On February 9, 2021, the Company and the Buyer-lessor agreed on a re-purchase price for the property and equipment, which included the outstanding balance of the financing plus accrued interest. The Company paid the full amount of the negotiated price during the fiscal nine months ended October 3, 2021. Accounts receivable financing In September 2016, the Company entered into an accounts receivable financing program (the “Financing Program”) with a financial institution. The Financing Program, which was fully paid off in June 2021 in connection with entry into the RPA (as defined below), was set to mature on January 24, 2022 and was secured by receivables from the Company’s U.S. business that are sold or contributed to a wholly-owned, consolidated, bankruptcy remote subsidiary. The bankruptcy remote subsidiary’s sole business consisted of the purchase or receipt of the receivables and subsequent granting of a security interest to the financial institution under the program, and its assets were available first to satisfy obligations and were not available to pay creditors of the Company’s other legal entities. Under the Financing Program, the Company could borrow up to the lower of $ 75.0 million or 85 % of the accounts receivable borrowing base. Interest on outstanding borrowings under the Financing Program was charged based on a per annum rate equal to the London Inter-bank Offered Rate (the “LIBOR Rate”) (with a floor of zero percent and as defined in the agreement) plus the LIBOR Rate margin ( 2.25 percentage points) if the related loan was a LIBOR Rate loan. Otherwise, the per annum rate was equal to a Base Rate (as defined in the Financing Program agreement) plus the base rate margin ( 1.25 percentage points). Interest was due and payable, in arrears, on the first day of each month. The Financing Program was also subject to termination under standard events of default as defined. On June 11, 2021, Ortho-Clinical Diagnostics FinanceCo I, LLC (“Ortho FinanceCo I”), a wholly owned receivables financing subsidiary of the Company, entered into a receivables purchase agreement (the “RPA”) with Wells Fargo Bank, N.A., as administrative agent (the “Agent”), and certain purchasers. Under the RPA, Ortho FinanceCo I may sell receivables in amounts up to a $ 75.0 million limit. Transfers of receivables under the RPA are accounted for as a sale by the Company, resulting in a reduction in accounts receivables on the unaudited consolidated balance sheet. The $ 75.0 million limit is subject to certain conditions, including that, at any date of determination, the aggregate capital paid to Ortho FinanceCo I does not exceed a “capital coverage amount,” equal to an adjusted net receivables pool balance minus a required reserve. Ortho FinanceCo I has guaranteed the prompt payment of the sold receivables, and to secure the prompt payment and performance of such guaranteed obligations, Ortho FinanceCo I has granted a security interest to the Agent, for the benefit of the purchasers, in all assets of Ortho FinanceCo I. The Company, in its capacity as master servicer under the RPA, is responsible for administering and collecting the receivables and has made customary representations, warranties, covenants and indemnities. The Company has also provided a performance guarantee for the benefit of Ortho FinanceCo I to cause the due and punctual performance by Ortho of its obligations as master servicer. The proceeds of the RPA were used, in part, to pay off the outstanding balance of the Financing Program. The impact on the Company’s unaudited consolidated statements of operations related to the RPA during the fiscal quarter and nine months ended October 3, 2021 was not material. The RPA is subject to customary events of termination for transactions of this type and, in addition, includes a financial covenant termination event if the “first lien net leverage ratio,” calculated as of the last day of each fiscal quarter, of the Company exceeds (i) 5.50 :1.00 for each fiscal quarter ending on or prior to September 30, 2022, and (ii) 5.00 :1:00 for each fiscal quarter ending thereafter. The RPA has a scheduled termination date which is the earlier of (i) June 11, 2024 , and (ii) the date that is 90 days prior to the maturity of the indebtedness incurred under the Company’s Senior Secured Credit Facilities. As of October 3, 2021, the Company was in full compliance with all debt covenant requirements. The following table provides the detail of amounts within Interest expense, net for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Interest expense: Dollar Term Loan Facility $ 10.2 $ 19.1 $ 34.8 $ 68.6 Euro Term Loan Facility 3.3 3.5 10.3 9.0 Revolving Credit Facility 1.5 0.2 2.1 3.4 2028 Notes 7.3 12.1 23.7 32.8 2025 Notes 4.4 7.3 14.3 8.8 2022 Notes — — — 14.1 Accounts Receivable Financing — 1.1 0.7 3.7 Amortization of: Deferred financing costs 1.6 2.2 4.9 6.5 Original issue discount 0.4 0.6 1.1 1.8 Derivative instruments and other 7.6 2.8 20.7 ( 0.1 ) Interest expense, net $ 36.1 $ 48.9 $ 112.5 $ 148.6 Future repayments Below is a schedule of required future repayments of all borrowings outstanding as of October 3, 2021: Remainder of 2021 $ 45.8 2022 63.5 2023 63.1 2024 62.8 2025 1,659.4 Thereafter 405.0 $ 2,299.5

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Oct. 03, 2021
Supplemental Balance Sheet Information [Abstract]
Supplemental Balance Sheet Information	(8) Supplemental balance sheet information Cash and cash equivalents and restricted cash within the unaudited consolidated balance sheets are presented below: October 3, 2021 January 3, 2021 Cash and cash equivalents $ 255.9 $ 132.8 Restricted cash included in Other assets 1.8 11.4 Cash, cash equivalents and restricted cash $ 257.7 $ 144.2 Accrued liabilities included in Total current liabilities consisted of the following: October 3, 2021 January 3, 2021 Accrued compensation and employee-related obligations $ 101.8 $ 110.5 Accrued commissions and rebates 28.3 24.9 Accrued taxes other than income 18.7 14.3 Accrued interest 17.3 42.2 Current portion of operating lease liabilities 12.0 15.1 Derivatives 3.2 10.3 Other accrued liabilities 70.3 67.4 Total accrued liabilities $ 251.5 $ 284.7

Collaborations and Other Relati

Collaborations and Other Relationships	9 Months Ended
	Oct. 03, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborations and other relationships	(9) Collaborations and other relationships In the normal course of business, the Company has entered into various collaboration arrangements which provide the Company with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by the Company’s collaborative partners. The arrangements are often entered into in order to share risks and rewards related to a specific program or product. The Company’s collaborative arrangements include agreements with respect to transition services and a number of on-going relationships. Grifols / Novartis Vaccines and Diagnostics, Inc. The Company and Grifols Diagnostic Solutions, Inc. (“Grifols”) have an ongoing collaboration arrangement (the “Joint Business”) to pursue income-generating opportunities through the development of certain intellectual properties (“IP”). The Company’s portion of the pre-tax net profit shared under the Joint Business was $ 21.3 million and $ 45.5 million during the fiscal quarter and nine months ended October 3, 2021 , respectively. The Company’s portion of the pre-tax net profit shared under the Joint Business was $ 13.4 million and $ 35.9 million during the fiscal quarter and nine months ended September 27, 2020, respectively. Quotient Limited In January 2015, the Company entered into an exclusive agreement with Quotient Limited (“Quotient”), a commercial-stage diagnostics company, to distribute and sell Quotient’s transfusion diagnostics platform MosaiQ™. Under the terms of a distribution and supply agreement, Quotient is responsible for the development and launch of MosaiQ™, while the Company will leverage its worldwide commercial capabilities to sell the product to customers. The Company has exclusive rights to distribute MosaiQ™ for the global patient testing market (for blood grouping) and the donor testing market in the developing world and Japan (for blood grouping and serological disease screening). Quotient retains all rights to commercialize MosaiQ™ in the developed world, excluding Japan, for the donor testing market. On September 4, 2020, the Company and Quotient amended the distribution and supply agreement and entered into a binding letter agreement (the “Letter Agreement”). Pursuant to the Letter Agreement, the Company made an initial, non-refundable upfront payment of $ 7.5 million to Quotient on the date of the Letter Agreement, and recorded a corresponding $ 7.5 million charge to Research and development expense for the fiscal quarter and nine months ended September 27, 2020. In addition to the initial $ 7.5 million upfront payment, the Company may be required to make up to an additional $ 60.0 million of payments upon achievement of certain regulatory milestones and commercial sales benchmarks, which include up to $ 25.0 million of payments upon the achievement by the Company of certain cumulative revenue milestones. The Company did not make such payments during the fiscal nine months ended October 3, 2021 and does not anticipate making any such payments for the remainder of fiscal year 2021. In the Letter Agreement, the Company and Quotient have agreed that the Company will have the right to distribute exclusively in the U.S., the European Economic Area, the U.K. and Switzerland a transfusion diagnostic patient immunohematology microarray (“PIM”), intended for use with Quotient’s MosaiQ Instruments, on which multiple compounds are placed which, when exposed to human blood samples, generate reactions that indicate the presence or absence of certain blood characteristics and antigens and is intended for immuno-hematological testing of the blood of medical patients during the course of their care or treatment. During the fiscal quarter and nine months ended October 3, 2021, under a separate supply agreement, the Company purchased inventories from a subsidiary of Quotient amounting to $ 5.1 million and $ 17.1 million, respectively. The Company purchased inventories from the Quotient subsidiary amounting to $ 6.4 million and $ 17.1 million during the fiscal quarter and nine months ended September 27, 2020, respectively. As of October 3, 2021 and January 3, 2021, Accounts payable included amounts related to purchases from the Quotient subsidiary of $ 2.9 million and $ 2.3 million, respectively. During both the fiscal quarter and nine months ended October 3, 2021 , sales to Quotient were $ 0.1 million. During the fiscal quarter and nine months ended September 27, 2020 , sales to Quotient were $ 0.1 million and $ 0.2 million, respectively. As of October 3, 2021 and January 3, 2021, amounts due from Quotient were immaterial.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 03, 2021
Income Tax Disclosure [Abstract]
Income Taxes	(10) Income taxes During the fiscal quarter ended October 3, 2021, the Company reported income before provision for income taxes of $ 20.7 million and recognized a provision for income taxes of $ 6.0 million , resulting in an effective tax rate of 29.1 % . During the fiscal nine months ended October 3, 2021, the Company incurred a loss before provision for income taxes of $ 20.0 million and recognized a provision for income taxes of $ 24.4 million , resulting in a negative effective tax rate of 122.2 % . The effective tax rate for the fiscal nine months ended October 3, 2021 differs from the U.S. federal statutory rate primarily due to (i) a net cost of $ 27.5 million for the impacts of operating losses in certain subsidiaries not being benefited due to the establishment of valuation allowances, (ii) a net benefit of $ 10.9 million related to non-U.S. earnings being taxed at rates that are different than the U.S. statutory rate, and (iii) a net cost of $ 10.6 million for the tax expense associated with the remeasurement of deferred tax assets and liabilities due to the enactment of new tax rates, primarily in the United Kingdom. During the fiscal quarter ended September 27, 2020, the Company incurred a loss before provision for income taxes of $ 38.8 million and recognized an income tax benefit of $ 10.3 million, resulting in an effective tax rate of 26.5 %. During the fiscal nine months ended September 27, 2020, the Company incurred a loss before provision for income taxes of $ 173.4 million and recognized an income tax benefit of $ 2.4 million, resulting in an effective tax rate of 1.4 %. The effective tax rate for the fiscal nine months ended September 27, 2020 differs from the U.S. federal statutory rate primarily due to (i) a net cost of $ 39 million for the impacts of operating losses in certain subsidiaries not being benefited due to the establishment of valuation allowances, (ii) a net benefit of $ 12 million related to the increase in the Company’s interest expense on prior year reserves for uncertain tax positions, and (iii) a net cost of $ 9.7 million due to the non-U.S. earnings being taxed at rates that are different than the U.S. statutory rate. The balance of unrecognized tax benefits at October 3, 2021 , not including interest and penalties, was $ 28.3 million, of which $ 23.8 million would affect the effective income tax rate in future periods, if recognized. The Company also recognizes interest and penalties related to unrecognized tax benefits in tax expense. At October 3, 2021 , the Company had approximately $ 6.7 million of interest and penalties accrued related to unrecognized tax benefits. The Company estimates that within the next twelve months, its uncertain tax positions, excluding interest, will not significantly decrease. Indemnification assets On January 16, 2014, Bermuda Holdco entered into a stock and asset purchase agreement (the “Acquisition Agreement”) of (i) certain assets and liabilities, and (ii) all of the equity interests and substantially all of the assets and liabilities of certain entities which, together with their subsidiaries, comprised the Ortho Clinical Diagnostics business from Johnson & Johnson. The Acquisition Agreement generally provided that Johnson & Johnson retained all income tax liabilities accrued as of the date of the acquisition, including reserves for unrecognized tax benefits. The indemnification receivable from Johnson & Johnson totaled $ 17.6 million and $ 17.0 million as of October 3, 2021 and January 3, 2021 , respectively. The Company recorded $ 0.2 million and $ 0.6 million of interest and penalties during the fiscal quarter and nine months ended October 3, 2021 , respectively. These receivables are included as a component of Other current assets and Other assets on the unaudited consolidated balance sheets.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Oct. 03, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(11) Stock-based compensation Stock-based compensation for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020 are presented in the unaudited consolidated statements of operations in the following captions: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Cost of revenue $ 0.1 $ 0.2 $ 0.4 $ 0.6 Selling, marketing and administrative expenses 4.9 2.1 18.9 5.4 Research and development expense 0.1 0.1 0.4 0.2 Total stock-based compensation $ 5.1 $ 2.4 $ 19.6 $ 6.2 On May 3, 2021, the Board of Directors approved the modifications to the vesting of restricted stock and Liquidity Event option awards held by certain current and former members of management. The modification of restricted stock pertained to an award granted to a current member of management, for which the original vesting pattern was on a cliff-vesting basis over a three-year period. Upon modification, the vesting for 50 % of the award was accelerated to six months from the date of the Company’s IPO. The result of the modification was an additional $ 0.3 million and $ 1.6 million of stock-based compensation expense recorded for the fiscal quarter and nine months ended October 3, 2021, respectively. There was no modification to the vesting conditions for the remaining 50 % of the award and no additional shares granted as a result of the modification. The total unrecognized expense relating to unvested shares for this award as of the fiscal quarter ended October 3, 2021 was $ 0.7 million and will be recognized over a period of one year . The other modification related to an award granted to a former member of management for which the original vesting was contingent on a certain liquidity event as defined by the option agreement. The modification changed the vesting for the award such that the entirety of the award vested on the date the modification was approved by the Board of Directors. The modification resulted in an additional $ 4.6 million of stock-based compensation expense recognized during the fiscal quarter ended July 4, 2021. The additional expense related to both award modifications is recorded as a component of Selling, marketing and administrative expenses.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Oct. 03, 2021
Segment Reporting [Abstract]
Segment and Geographic Information	(1 2) Segment and geographic information The Company has three geographically-based reportable segments: Americas, Europe, the Middle East and Africa (“EMEA”), and Greater China. Although all three segments are engaged in the marketing, distribution and sale of diagnostic instruments and assays for hospitals, laboratories and/or blood and plasma centers worldwide, each region is managed separately to better align with the market dynamics of the specific geographic region. Japan and Asia Pacific (“ASPAC”) are immaterial operating segments not considered as reportable segments and are included in “Other.” Net revenue by segment is as follows: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Americas $ 306.5 $ 264.2 $ 924.2 $ 755.8 EMEA 67.2 58.6 203.5 168.2 Greater China 85.6 72.7 199.1 162.3 Net revenue of reportable segments $ 459.3 $ 395.5 $ 1,326.8 $ 1,086.3 Other 63.2 55.6 195.1 163.2 Net revenue $ 522.5 $ 451.1 $ 1,521.8 $ 1,249.6 Effective January 4, 2021, the Company changed the basis for which it measures segment profit or loss from Management EBITDA to Adjusted EBITDA. The new basis has been retroactively applied to the prior year period presented. Adjusted EBITDA by segment is as follows: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Americas $ 125.0 $ 116.8 $ 394.2 $ 329.9 EMEA 17.2 10.7 47.7 31.4 Greater China 42.2 41.1 91.7 78.9 Other 19.0 16.7 61.4 49.9 Corporate(a) ( 63.8 ) ( 65.9 ) ( 174.8 ) ( 167.8 ) Adjusted EBITDA $ 139.6 $ 119.5 $ 420.1 $ 322.4 (a) Corporate primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and information technology, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards. The reconciliation of Net income (loss) to Adjusted EBITDA is as follows: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Net income (loss) $ 14.7 $ ( 28.5 ) $ ( 44.4 ) $ ( 171.0 ) Interest expense, net 36.1 48.9 112.5 148.6 Provision for (benefit from) income taxes 6.0 ( 10.3 ) 24.4 ( 2.4 ) Depreciation and amortization 80.8 79.9 246.6 239.6 Stock-based compensation 5.0 2.4 19.5 6.2 Restructuring and severance-related costs 1.7 4.7 4.7 9.3 Arbitration award ( 7.4 ) — ( 7.4 ) — Tax indemnification (income) expense, net ( 0.2 ) 16.5 ( 0.6 ) 11.6 Loss on extinguishment of debt — — 50.3 12.6 Quotient upfront payment — 7.5 — 7.5 Unrealized foreign currency exchange (gains) losses, — ( 6.3 ) — 46.0 Other adjustments 2.9 4.7 14.5 14.4 Adjusted EBITDA $ 139.6 $ 119.5 $ 420.1 $ 322.4 For the fiscal quarter and nine months ended September 27, 2020 , unrealized foreign currency exchange (gains) losses, net relate to the remeasurement of transactions denominated in foreign currencies, primarily intercompany loans. Beginning in fiscal 2021, the Company initiated programs to mitigate the impact of foreign currency exchange rate fluctuations from intercompany loans. The Company recognized unrealized foreign currency exchange net gains of $ 4.3 million in the fiscal quarter ended October 3, 2021 and $ 38.0 million in the fiscal nine months ended October 3, 2021 . The Company intends for these programs to mitigate the impact of foreign currency exchange rate fluctuations related to intercompany loans in current and future periods. Therefore, effective January 4, 2021, the Company no longer excludes noncash unrealized gains and losses from Adjusted EBITDA.

Noncash Investing and Financing

Noncash Investing and Financing Activities	9 Months Ended
	Oct. 03, 2021
Noncash Investing And Financing Items [Abstract]
Noncash Investing and Financing Activities	(13) Noncash investing and financing activities During the fiscal nine months ended October 3, 2021 and September 27, 2020 , the Company made noncash transfers of instrument inventories from Inventories to Property, plant and equipment, net of $ 82.6 million and $ 91.5 million , respectively. As of October 3, 2021 and January 3, 2021 , Accounts payable and Accrued liabilities included amounts related to purchases of property, plant and equipment and capitalized internal-use software costs of $ 10.4 million and $ 11.4 million, respectively. As of September 27, 2020 and December 29, 2019 , Accounts payable and Accrued liabilities included amounts related to purchases of property, plant and equipment and capitalized internal-use software costs of $ 3.5 million and $ 14.1 million, respectively. The changes in these balances are excluded from changes in Accounts payable and Accrued liabilities in the unaudited consolidated statements of cash flows. There was $ 3.0 million of initial public offering costs remaining in Accounts payable and Accrued liabilities as of January 3, 2021. There were no amounts related to initial public offering costs in Accounts payable and Accrued liabilities as of October 3, 2021 .

Related Party Transactions

Related Party Transactions	9 Months Ended
	Oct. 03, 2021
Related Party Transactions [Abstract]
Related Party Transactions	(14) Related party transactions The Company entered into consulting services agreements with Carlyle Investment Management, L.L.C. (“CIM”), pursuant to which the Company pays CIM a fee for advisory, consulting and other services to be provided to the Company (the “Consulting Services Agreement”). Pursuant to the Consulting Services Agreement, which has an initial term of ten years , the Company pays an annual management fee to CIM of $ 3.0 million (the “Management Fee”). The Management Fee is payable on a quarterly basis. The Company will also reimburse CIM’s reasonable out-of-pocket expenses incurred in connection with services provided pursuant to the Consulting Services Agreement, and the Company may pay CIM additional fees associated with other future transactions or in consideration of any additional services provided to the Company under the Consulting Services Agreement. During both the fiscal quarter ended October 3, 2021 and September 27, 2020, the Company recorded $ 0.8 million of Management Fee and other out-of-pocket expenses. During both the fiscal nine months ended October 3, 2021 and September 27, 2020 , the Company recorded $ 2.3 million of Management Fee and other out-of-pocket expenses. As of January 3, 2021 and October 3, 2021, amounts due to CIM were immaterial. The Company, as part of the normal course of business, entered into agreements to sell products and provide services to health care diagnostics companies that are portfolio companies of a fund affiliated with Carlyle. During the fiscal quarter ended October 3, 2021 and September 27, 2020, the Company recognized revenues from business conducted with these health care diagnostics companies of $ 3.2 million and $ 0.4 million, respectively. During the fiscal nine months ended October 3, 2021 and September 27, 2020 , the Company recognized revenues from business conducted with these health care diagnostics companies of $ 5.0 million and $ 1.3 million, respectively. As of both October 3, 2021 and January 3, 2021, Accounts receivable included amounts related to these health care diagnostics companies of $ 1.2 million. The Company, as part of the normal course of business, purchased inventories from a healthcare equipment company that is a portfolio company of a fund affiliated with Carlyle. During the fiscal quarter and nine months ended October 3, 2021 , the Company recorded expenses for business conducted with this healthcare equipment company of $ 1.3 million and $ 2.2 million, respectively. The Company did no t record any expenses for business conducted with this healthcare equipment company during fiscal quarter and nine months ended September 27, 2020. As of October 3, 2021, Accounts payable included immaterial amounts due to this healthcare equipment company. As of January 3, 2021, there were no amounts due to this healthcare equipment company. Portfolio companies of funds affiliated with Carlyle provide Information Technology (“IT”) services to the Company. During the fiscal quarter ended October 3, 2021 and September 27, 2020 , the Company recorded expenses for business conducted with these companies of $ 0.3 million and $ 0.2 million, respectively. During the fiscal nine months ended October 3, 2021 and September 27, 2020 , the Company recorded expenses for business conducted with these companies of $ 1.0 million and $ 0.2 million, respectively. As of both October 3, 2021 and January 3, 2021, Accounts payable included amounts related to these companies of $ 0.1 million. A portfolio company of a fund affiliated with Carlyle provides consulting services to the Company. During the fiscal quarter ended October 3, 2021 and September 27, 2020 , the Company recorded expenses for business conducted with this portfolio company of $ 0.1 million and $ 0.3 million, respectively. During the fiscal nine months ended October 3, 2021 and September 27, 2020, the Company recorded expenses for business conducted with this portfolio company of $ 1.3 million and $ 0.7 million, respectively. As of January 3, 2021, Accounts payable included amounts related to this portfolio company of $ 0.3 million. As of October 3, 2021, there were no amounts due to this portfolio company. A security services company that is affiliated with Carlyle provides services to the Company at one of its facilities. This was a new Carlyle investment in 2021. During the fiscal quarter and nine months ended October 3, 2021, the Company recorded expenses for these services of $ 0.2 million and $ 0.8 million, respectively. As of both October 3, 2021 and January 3, 2021, Accounts payable included $ 0.1 million of amounts due to this company. A pharmacy benefit management organization that is a portfolio company of a fund affiliated with Carlyle provides pharmacy services to the Company. During the fiscal quarter ended October 3, 2021 and September 27, 2020 , the Company recorded expenses for business conducted with this pharmacy benefit management organization of $ 1.5 million and $ 1.6 million, respectively. During the fiscal nine months ended October 3, 2021 and September 27, 2020 , the Company recorded expenses for business conducted with this pharmacy benefit management organization of $ 4.4 million and $ 4.6 million, respectively. As of October 3, 2021, Accounts payable included amounts related to this pharmacy benefit management organization of $ 0.4 million. As of January 3, 2021, Accrued liabilities included amounts related to this pharmacy benefit management organization of $ 0.6 million. As part of the normal course of business, the Company may purchase from or sell to portfolio companies of funds affiliated with Carlyle or the Company’s officers and directors. These expenses and revenues are not expected to be material.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 03, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(15) Commitments and contingencies At times, the entities that carry out the Company’s business are the subject of governmental investigations and various legal actions and claims from governmental agencies and other parties. The outcomes of these matters are not within the Company’s complete control and may not be known for prolonged periods of time. The Company records a liability in the unaudited consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from these matters are inherently difficult to predict. The Company is involved in an arbitration related to a commercial contract dispute. Although the Company believes it has meritorious defenses against the claim which it intends to pursue vigorously, arbitration is inherently uncertain and it could result in an unfavorable ruling to the Company. Given the early stage of this matter, an estimate of the possible loss or range of loss cannot be made at this time.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 03, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	(16) Fair value measurements The carrying amount of cash and cash equivalents, current accounts receivable, accounts payable, and short term borrowings approximates fair value because of their short outstanding terms. The estimated fair values of the Company’s Long-term borrowings were based on trades as reported by a third-party bond pricing service. Due to the infrequency of trades of the Notes and Term Loans, these inputs are considered Level 2 inputs. The following table presents the fair values of Long-term borrowings: October 3, 2021 January 3, 2021 Long-term borrowings: Dollar Term Loan Facility $ 1,496.8 $ 2,627.7 Euro Term Loan Facility 357.1 401.1 2028 Notes 434.4 710.4 2025 Notes 252.0 424.0

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Oct. 03, 2021
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	(17) Derivative instruments and hedging activities The Company selectively uses derivative and non-derivative instruments to manage market risk associated with changes in interest rates and foreign currency exchange rates. The use of derivatives is intended for hedging purposes only, and the Company does not enter into derivative transactions for speculative purposes. The Company’s derivative contracts do not require cash collateral. Interest rate hedging instruments The Company’s interest rate risk relates primarily to interest rate exposures on variable rate debt including the Senior Secured Credit Facilities. Refer to Note 7 for additional information on the currently outstanding components of the Senior Secured Credit Facilities. The Company entered into a series of interest rate cap and swap agreements to hedge the related risk of the variability to the Company’s cash flows due to the rates specified for these credit facilities. The Company designates certain interes t rate derivative instruments as cash flow hedges, including a portion of the outstanding interest rate swaps. The Company records gains and losses due to changes in fair value of the derivatives within Other comprehensive income (“OCI”) and reclassifies these amounts to Interest expense, net in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the remaining gain or loss within Accumulated other comprehensive income (“AOCI”) is reclassified to earnings at that time. The pre-tax unrealized loss of $ 16.2 million within OCI as of October 3, 2021 is expected to be reclassified to earnings in the next 12 months. The following tables summarize the Company’s interest rate derivative agreements as of October 3, 2021: Effective date Expiration date Interest rate cap amount Notional amount Hedge designation December 31, 2020 December 31, 2023 3.5 % $ 1,500.0 Non-designated Effective date Expiration date Description Fixed rate Floating rate Notional amount (a) Hedge designation September 27, December 31, Pay fixed, 1.635 % 1-month LIBOR rate $ 1,500.0 Cash Flow (a) The notional value of this instrument is expected to be $ 1,000 million in fiscal 2022 and $ 500 million in fiscal 2023. The Company previously entered into an interest rate cap that was designated as a cash flow hedge. During the fiscal quarter ended September 29, 2019, the Co mpany de-designated its 3.5 % interest rate caps upon entering into the interest rate swap agreement that hedges a portion of the Company’s borrowings under the Senior Secured Credit Facilities. Upon de-designation, the Company began prospectively recognizing mark-to-market gains and losses within Other expense, net on the interest rate caps. The remaining loss on the interest rate caps that was deferred in OCI was amortized to Interest expense, net until the Company concluded that a portion of the interest on the Company’s previously hedged borrowings was no longer probable of being paid due to the pay down of a portion of the borrowings using proceeds from the IPO. Accordingly, $ 0.6 million of losses that had previously been deferred within OCI were released into Interest expense, net during the fiscal quarter ended April 4, 2021. During the fiscal quarter and nine months ended October 3, 2021, the Company reclassified $ 0.9 million and $ 2.6 million, respectively, of deferred losses from AOCI to Interest expense, net. As of October 3, 2021 , the remaining balance of the deferred loss in AOCI was $ 6.7 million. As of January 3, 2021, the balance of the deferred loss in AOCI was $ 9.8 million. During the fiscal quarter ended April 4, 2021, the Company concluded that a portion of the interest on the Company’s previously hedged borrowings related to the interest rate swap was no longer probable of being paid due to the pay down of a portion of the borrowings using the proceeds from the IPO. Due to this reduction in the hedged borrowings, the Company de-designated the hedging relationship, and contemporaneously re-designated the remaining borrowings. Accordingly, $ 3.1 million of losses that had previously been deferred within AOCI were released into Interest expense, net during the fiscal quarter ended April 4, 2021. As of October 3, 2021, the remaining balance of the deferred loss in AOCI was $ 24.5 million. Currency hedging instruments The Company has currency risk exposures relating primarily to foreign currency denominated monetary assets and liabilities and forecasted foreign currency denominated intercompany and third-party transactions. The Company uses foreign currency forward, option contracts and cross currency swaps to manage its currency risk exposures. The Company’s foreign currency forward contracts are denominated primarily in Australian Dollar, Brazilian Real, British Pound, Canadian Dollar, Chilean Peso, Chinese Yuan/Renminbi, Colombian Peso, Euro, Indian Rupee, Japanese Yen, Mexican Peso, Philippine Peso, Swiss Franc and the Thai Baht. The Company designates certain foreign currency forward contracts as cash flow hedges. The Company records gains and losses due to changes in fair value of the derivatives within OCI and reclassifies these amounts to Cost of revenue, excluding amortization of intangible assets in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the remaining gain or loss within AOCI is reclassified to earnings at that time. The pre-tax unrealized gain of $ 1.6 million within OCI as of October 3, 2021 is expected to be reclassified to earnings in the next 12 months. Foreign exchange risk is also managed through the use of foreign currency debt. During the fiscal quarter ended October 3, 2021, € 260.0 million ($ 301.5 million) of the Company's senior secured Euro Term Loan Facility has been designated as, and is effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the Euro-denominated debt instruments are included in foreign currency translation adjustments within AOCI. The Company also enters into foreign currency forward contracts that are not part of designated hedging relationships, which are intended to mitigate exchange rate risk of monetary assets and liabilities and related forecasted transactions. The Company records these non-designated derivatives at mark-to-market with gains and losses recognized currently in earnings within Other expense, net. Concurrent with the issuance of the 2028 Notes, the Company entered into U.S. Dollar to Japanese Yen cross currency swaps for total notional of $ 350.0 million at a weighted average interest rate of 5.56 %, with a five-year term to lower interest expense on the 2028 Notes. These cross currency swaps were not designated for hedge accounting, and consequently, changes in their fair value are recorded to Other expense, net. The Company terminated the cross currency swaps on April 1, 2021 and received $ 12.8 million of cash from net settlement during the fiscal nine months ended October 3, 2021. The following table provides details of the currency hedging instruments outstanding as of October 3, 2021: Description Notional amount Hedge designation Foreign Currency Forward Contracts $ 161.5 Cash Flow Hedge Foreign Currency Forward Contracts 262.2 Non-designated Gains and losses from designated derivative and non-derivative instruments within AOCI during the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020 were recorded as follows: Designated Hedging Instruments Amount of loss Location of amounts Amount of loss Fiscal Quarter Ended October 3, 2021 Cash flow hedges: Foreign currency forward contracts $ ( 1.0 ) Cost of revenue, excluding amortization of intangible assets $ 1.1 Interest rate derivative contracts — Interest expense, net 5.9 Net investment hedges: Foreign currency-denominated debt (a) 0.8 N/A N/A Fiscal Nine Months Ended October 3, 2021 Cash flow hedges: Foreign currency forward contracts $ ( 3.7 ) Cost of revenue, excluding amortization of intangible assets $ 2.7 Interest rate derivative contracts ( 1.8 ) Interest expense, net 20.9 Net investment hedges: Foreign currency-denominated debt (a) 3.8 N/A N/A (a) The amount of loss (gain) recognized in OCI for the foreign-currency denominated debt is presented within the CTA component of OCI. These gains and losses will remain in CTA until the related hedged item affects earnings, which would occur upon disposal or complete or substantial liquidation of the underlying hedged entities. Designated Hedging Instruments Amount of loss Location of amounts Amount of loss Fiscal Quarter Ended September 27, 2020 Cash flow hedges: Foreign currency forward contracts $ 1.5 Cost of revenue, excluding amortization of intangible assets $ ( 2.0 ) Interest rate derivative contracts ( 0.5 ) Interest expense, net 0.5 Fiscal Nine Months Ended September 27, 2020 Cash flow hedges: Foreign currency forward contracts $ ( 2.2 ) Cost of revenue, excluding amortization of intangible assets $ ( 4.5 ) Interest rate derivative contracts (a) 47.1 Interest expense, net ( 1.9 ) (a) For the fiscal nine months ended September 27, 2020, the $ 47.1 million loss recognized in OCI for the interest rate derivative contracts does not include the $ 3.7 million loss from the cumulative effect of change in accounting standard, which is presented in Note 18. The following tables present the effect of the Company’s designated derivative instruments within Interest expense, net and Cost of revenue, excluding amortization of intangible assets in the unaudited consolidated statements of operations: Fiscal quarter ended October 3, 2021 Fiscal quarter ended September 27, 2020 Interest expense, net Cost of revenue, excluding amortization of intangible assets Interest expense, net Cost of revenue, excluding amortization of intangible assets Total amount of line item in unaudited consolidated statements of operations where effects of hedges are presented: $ 36.1 $ 252.4 $ 48.9 $ 234.1 Effects of cash flow hedging relationships Foreign currency forward contracts: Amount of loss (gain) reclassified from AOCI into income N/A 1.1 N/A ( 2.0 ) Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring N/A — N/A ( 0.1 ) Interest rate derivative contracts: Amount of net loss reclassified from AOCI into income 5.9 N/A 0.5 N/A Fiscal nine months ended October 3, 2021 Fiscal nine months ended September 27, 2020 Interest expense, net Cost of revenue, excluding amortization of intangible assets Interest expense, net Cost of revenue, excluding amortization of intangible assets Total amount of line item in unaudited consolidated statements of operations in which effects of hedges are presented: $ 112.5 $ 748.7 $ 148.6 $ 650.2 Effects of cash flow hedging relationships Foreign currency forward contracts: Amount of loss (gain) reclassified from AOCI into income N/A 2.7 N/A ( 4.5 ) Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring N/A — N/A ( 0.2 ) Interest rate derivative contracts: Amount of loss (gain) reclassified from AOCI into income 20.9 N/A ( 1.9 ) N/A Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring (a) 3.7 N/A — N/A (a) The amount is included within the total amount of loss (gain) reclassified from accumulated OCI into income. The following table presents mark-to-market (gains) and losses on non-designated derivatives recognized currently within the unaudited consolidated statements of operations: Location of amounts Fiscal Quarter Ended Fiscal Nine Months Ended Non-designated hedging instruments recognized in earnings on derivatives October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Interest rate derivative contracts Other expense, net $ 0.1 $ 0.4 $ — $ 1.3 Foreign currency forward contracts Other expense, net ( 1.6 ) 1.5 32.6 3.1 Cross-currency interest rate swap contracts Other expense, net — 2.5 ( 24.0 ) ( 2.6 ) The following table presents the location and fair values of designated hedging instruments recognized within the unaudited consolidated balance sheets. The fair values of d esignated hedging instruments have been determined using Level 2 inputs. October 3, 2021 January 3, 2021 Interest rate derivative contracts: Accrued liabilities $ 0.1 $ 0.1 Other liabilities 25.4 44.1 Foreign currency forward contracts: Other current assets 3.8 4.2 Accrued liabilities 2.4 10.0 The following table presents the location and fair values of non-designated hedging instruments recognized within the unaudited consolidated balance sheets. The fair values of non-designated hedging instruments have been determined using Level 2 inputs. October 3, 2021 January 3, 2021 Interest rate derivative contracts: Accrued liabilities $ — $ 0.1 Other liabilities 6.8 11.1 Foreign currency forward contracts: Other current assets 1.7 0.3 Accrued liabilities 0.7 0.1 Cross currency interest rate swap contracts: Other current assets — 2.0 Other liabilities — 10.8

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Oct. 03, 2021
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	(18) Accumulated other comprehensive income (loss) The balances of accumulated other comprehensive income (loss), net of tax, were as follows for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020: Pension and Foreign Interest Unrealized Accumulated Balance at July 4,2021 $ ( 4.5 ) $ ( 0.6 ) $ ( 37.1 ) $ ( 12.8 ) $ ( 54.9 ) Current period deferrals — 1.0 — ( 13.9 ) ( 12.9 ) Amounts reclassified to net income — 1.1 5.9 — 7.0 Net change — 2.1 5.9 ( 13.9 ) ( 5.9 ) Balance at October 3, 2021 $ ( 4.5 ) $ 1.5 $ ( 31.2 ) $ ( 26.7 ) $ ( 61.0 ) Pension and Foreign Interest Unrealized Accumulated Balance at June 28, 2020 $ ( 4.3 ) $ 3.9 $ ( 55.8 ) $ ( 70.9 ) $ ( 127.1 ) Current period deferrals — ( 1.5 ) 0.5 8.1 7.1 Amounts reclassified to net loss — ( 2.0 ) 0.5 — ( 1.5 ) Net change — ( 3.5 ) 1.0 8.1 5.6 Balance at September 27, 2020 $ ( 4.3 ) $ 0.4 $ ( 54.8 ) $ ( 62.8 ) $ ( 121.5 ) Pension and Foreign Interest Unrealized Accumulated Balance at January 3, 2021 $ ( 4.5 ) $ ( 4.9 ) $ ( 53.9 ) $ ( 5.1 ) $ ( 68.4 ) Current period deferrals — 3.7 1.8 ( 21.7 ) ( 16.1 ) Amounts reclassified to net loss — 2.7 20.9 — 23.6 Net change — 6.4 22.7 ( 21.7 ) 7.5 Balance at October 3, 2021 $ ( 4.5 ) $ 1.5 $ ( 31.2 ) $ ( 26.7 ) $ ( 61.0 ) Pension and Foreign Interest Unrealized Accumulated Balance at December 29, 2019 $ ( 4.3 ) $ 2.7 $ ( 5.8 ) $ ( 64.5 ) $ ( 71.9 ) Current period deferrals — 2.2 ( 43.4 ) 1.7 ( 39.5 ) Amounts reclassified to net loss — ( 4.5 ) ( 1.9 ) — ( 6.4 ) Cumulative effect of change in accounting — — ( 3.7 ) — ( 3.7 ) Net change — ( 2.3 ) ( 49.0 ) 1.7 ( 49.6 ) Balance at September 27, 2020 $ ( 4.3 ) $ 0.4 $ ( 54.8 ) $ ( 62.8 ) $ ( 121.5 )

Other (Income) Expense, Net

Other (Income) Expense, Net	9 Months Ended
	Oct. 03, 2021
Other Income And Expenses [Abstract]
Other (Income) Expense, Net	(19) Other (income) expense, net Other income, net was $ 2.6 million for the fiscal quarter ended October 3, 2021 , comprised primarily of $ 0.7 million of net foreign currency gains and fair value gains of $ 1.5 million from interest rate caps. Other expense, net was $ 50.8 million for the fiscal nine months ended October 3, 2021 and was comprised primarily of loss on early extinguishment of debt of $ 50.3 million, which was related to the use of proceeds from the IPO to redeem portions of the Company’s outstanding 2025 Notes, 2028 Notes and Dollar Term Loan Facility. Other income, net was $ 5.9 million for the fiscal quarter ended September 27, 2020 , comprised primarily of $ 5.4 million of net foreign currency gains, of which $ 3.9 million was unrealized, primarily related to intercompany loans denominated in currencies other than the functional currency of the affected subsidiaries and fair value gains of $ 0.5 million from interest rate caps. Other expense, net was $ 61.1 million for the fiscal nine months ended September 27, 2020 and was comprised primarily of $ 49.4 million of net foreign currency losses, of which $ 51.1 million was unrealized, mainly related to intercompany loans denominated in currencies other than the functional currency of the affected subsidiaries, and loss on early extinguishment of $ 12.6 million related to debt refinancing activities.

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Oct. 03, 2021
Earnings Per Share [Abstract]
Schedule of weighted-average number of ordinary shares used in computation of basic and diluted net income (loss) per share	The weighted-average number of ordinary shares used in the computation of basic and diluted net income (loss) per share were as follows: Fiscal Quarter Ended Fiscal Nine Months Ended (In millions) October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Basic weighted-average ordinary shares outstanding 235.6 146.4 225.4 146.4 Effect of stock options, unvested restricted shares and 7.2 — — — Diluted weighted-average ordinary shares 242.8 146.4 225.4 146.4
Schedule of Total Outstanding Ordinary Share Equivalents Unaffected by the Treasury Stock Method Weighted-Average Calculation [Table Text Block]	The following table provides the total outstanding ordinary share equivalents, unaffected by the treasury stock method weighted-average calculation, as of the end of each period below: Fiscal Quarter Ended Fiscal Nine Months Ended (In millions) October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Stock options 13.9 16.2 13.9 16.2 Unvested restricted shares and restricted stock 0.6 0.3 0.6 0.3 14.5 16.5 14.5 16.5

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Oct. 03, 2021
Revenue From Contract With Customer [Abstract]
Schedule of Balance of Contract Assets Recorded in Consolidated Balance Sheets	The balance of Contract assets recorded in the Company’s consolidated balance sheets were as follows: October 3, 2021 January 3, 2021 Other current assets $ 47.8 $ 40.4 Other assets 0.8 2.4 Total contract assets $ 48.7 $ 42.8
Summary of Net Revenue by Line of Business	The following table summarizes Net revenue by line of business for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Clinical Laboratories $ 336.6 $ 300.1 $ 993.9 $ 816.7 Transfusion Medicine 170.7 140.6 494.5 414.5 Other Product Revenue — 3.3 5.6 3.7 Total Product Revenue 507.4 444.1 1,494.1 1,234.9 Collaborations and Other Revenue 15.1 7.0 27.8 14.7 Net Revenue $ 522.5 $ 451.1 $ 1,521.8 $ 1,249.6

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 03, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	The Company’s inventories were as follows: October 3, 2021 January 3, 2021 Raw materials and supplies $ 71.5 $ 77.2 Goods in process 38.3 35.2 Finished goods 198.6 166.3 Total Inventories $ 308.3 $ 278.7

Borrowings and Other Arrangem_2

Borrowings and Other Arrangements (Tables)	9 Months Ended
	Oct. 03, 2021
Debt Instrument [Line Items]
Components of Borrowings	As of October 3, 2021 and January 3, 2021, the components of borrowings were as follows: October 3, 2021 January 3, 2021 Senior Secured Credit Facilities Dollar Term Loan Facility $ 1,292.8 $ 2,185.5 Euro Term Loan Facility 357.2 408.9 Revolving Credit Facility — — 2028 Notes 405.0 675.0 2025 Notes 240.0 400.0 Accounts Receivable Financing — 75.0 Sale and Leaseback Financing — 20.5 Finance lease obligation 0.8 1.0 Other short-term borrowings 0.8 0.9 Other long-term borrowings 2.9 3.9 Unamortized deferred financing costs ( 22.6 ) ( 40.9 ) Unamortized original issue discount ( 5.6 ) ( 11.3 ) Total borrowings 2,271.3 3,718.5 Less: Current portion ( 64.4 ) ( 160.0 ) Long-term borrowings $ 2,206.9 $ 3,558.5
Schedule of Interest Expense, Net	The following table provides the detail of amounts within Interest expense, net for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Interest expense: Dollar Term Loan Facility $ 10.2 $ 19.1 $ 34.8 $ 68.6 Euro Term Loan Facility 3.3 3.5 10.3 9.0 Revolving Credit Facility 1.5 0.2 2.1 3.4 2028 Notes 7.3 12.1 23.7 32.8 2025 Notes 4.4 7.3 14.3 8.8 2022 Notes — — — 14.1 Accounts Receivable Financing — 1.1 0.7 3.7 Amortization of: Deferred financing costs 1.6 2.2 4.9 6.5 Original issue discount 0.4 0.6 1.1 1.8 Derivative instruments and other 7.6 2.8 20.7 ( 0.1 ) Interest expense, net $ 36.1 $ 48.9 $ 112.5 $ 148.6
Schedule of Required Future Repayments of all Borrowings Outstanding	Below is a schedule of required future repayments of all borrowings outstanding as of October 3, 2021: Remainder of 2021 $ 45.8 2022 63.5 2023 63.1 2024 62.8 2025 1,659.4 Thereafter 405.0 $ 2,299.5
2025 Notes
Debt Instrument [Line Items]
Schedule of Redemption Prices Expressed as Percentages of Principal Amount	On or after June 1, 2022 , the Issuers have the option to redeem all or part of the 2025 Notes at the following redemption prices (expressed as percentages of principal amount): Year Price 2022 103.688 % 2023 101.844 % 2024 and thereafter 100.000 %
2028 Notes
Debt Instrument [Line Items]
Schedule of Redemption Prices Expressed as Percentages of Principal Amount	On or after February 1, 2023 , the Issuers have the option to redeem all or part of the 2028 Notes at the following redemption prices (expressed as percentages of principal amount): Year Price 2023 103.625 % 2024 101.813 % 2025 and thereafter 100.000 %

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Oct. 03, 2021
Supplemental Balance Sheet Information [Abstract]
Schedule of Cash and Cash Equivalents and Restricted Cash	Cash and cash equivalents and restricted cash within the unaudited consolidated balance sheets are presented below: October 3, 2021 January 3, 2021 Cash and cash equivalents $ 255.9 $ 132.8 Restricted cash included in Other assets 1.8 11.4 Cash, cash equivalents and restricted cash $ 257.7 $ 144.2
Schedule of Accrued Liabilities	Accrued liabilities included in Total current liabilities consisted of the following: October 3, 2021 January 3, 2021 Accrued compensation and employee-related obligations $ 101.8 $ 110.5 Accrued commissions and rebates 28.3 24.9 Accrued taxes other than income 18.7 14.3 Accrued interest 17.3 42.2 Current portion of operating lease liabilities 12.0 15.1 Derivatives 3.2 10.3 Other accrued liabilities 70.3 67.4 Total accrued liabilities $ 251.5 $ 284.7

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Oct. 03, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock-Based Compensation Under Statements Of Operations	Stock-based compensation for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020 are presented in the unaudited consolidated statements of operations in the following captions: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Cost of revenue $ 0.1 $ 0.2 $ 0.4 $ 0.6 Selling, marketing and administrative expenses 4.9 2.1 18.9 5.4 Research and development expense 0.1 0.1 0.4 0.2 Total stock-based compensation $ 5.1 $ 2.4 $ 19.6 $ 6.2

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Oct. 03, 2021
Segment Reporting [Abstract]
Net Revenue by Segment	Net revenue by segment is as follows: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Americas $ 306.5 $ 264.2 $ 924.2 $ 755.8 EMEA 67.2 58.6 203.5 168.2 Greater China 85.6 72.7 199.1 162.3 Net revenue of reportable segments $ 459.3 $ 395.5 $ 1,326.8 $ 1,086.3 Other 63.2 55.6 195.1 163.2 Net revenue $ 522.5 $ 451.1 $ 1,521.8 $ 1,249.6
Adjusted EBITDA by Segment	Adjusted EBITDA by segment is as follows: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Americas $ 125.0 $ 116.8 $ 394.2 $ 329.9 EMEA 17.2 10.7 47.7 31.4 Greater China 42.2 41.1 91.7 78.9 Other 19.0 16.7 61.4 49.9 Corporate(a) ( 63.8 ) ( 65.9 ) ( 174.8 ) ( 167.8 ) Adjusted EBITDA $ 139.6 $ 119.5 $ 420.1 $ 322.4 Corporate primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and information technology, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.
Reconciliation of Net Loss to Adjusted EBITDA	The reconciliation of Net income (loss) to Adjusted EBITDA is as follows: Fiscal Quarter Ended Fiscal Nine Months Ended October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Net income (loss) $ 14.7 $ ( 28.5 ) $ ( 44.4 ) $ ( 171.0 ) Interest expense, net 36.1 48.9 112.5 148.6 Provision for (benefit from) income taxes 6.0 ( 10.3 ) 24.4 ( 2.4 ) Depreciation and amortization 80.8 79.9 246.6 239.6 Stock-based compensation 5.0 2.4 19.5 6.2 Restructuring and severance-related costs 1.7 4.7 4.7 9.3 Arbitration award ( 7.4 ) — ( 7.4 ) — Tax indemnification (income) expense, net ( 0.2 ) 16.5 ( 0.6 ) 11.6 Loss on extinguishment of debt — — 50.3 12.6 Quotient upfront payment — 7.5 — 7.5 Unrealized foreign currency exchange (gains) losses, — ( 6.3 ) — 46.0 Other adjustments 2.9 4.7 14.5 14.4 Adjusted EBITDA $ 139.6 $ 119.5 $ 420.1 $ 322.4

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 03, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Values of Long-term Borrowings	The following table presents the fair values of Long-term borrowings: October 3, 2021 January 3, 2021 Long-term borrowings: Dollar Term Loan Facility $ 1,496.8 $ 2,627.7 Euro Term Loan Facility 357.1 401.1 2028 Notes 434.4 710.4 2025 Notes 252.0 424.0

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Oct. 03, 2021
Schedule of Interest Rate Derivative Agreements	The following tables summarize the Company’s interest rate derivative agreements as of October 3, 2021: Effective date Expiration date Interest rate cap amount Notional amount Hedge designation December 31, 2020 December 31, 2023 3.5 % $ 1,500.0 Non-designated Effective date Expiration date Description Fixed rate Floating rate Notional amount (a) Hedge designation September 27, December 31, Pay fixed, 1.635 % 1-month LIBOR rate $ 1,500.0 Cash Flow (a) The notional value of this instrument is expected to be $ 1,000 million in fiscal 2022 and $ 500 million in fiscal 2023.
Schedule of Currency Hedging Instruments Outstanding	The following table provides details of the currency hedging instruments outstanding as of October 3, 2021: Description Notional amount Hedge designation Foreign Currency Forward Contracts $ 161.5 Cash Flow Hedge Foreign Currency Forward Contracts 262.2 Non-designated
Schedule of Gains and Losses from Designated Derivative and Non-derivative Instruments	Gains and losses from designated derivative and non-derivative instruments within AOCI during the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020 were recorded as follows: Designated Hedging Instruments Amount of loss Location of amounts Amount of loss Fiscal Quarter Ended October 3, 2021 Cash flow hedges: Foreign currency forward contracts $ ( 1.0 ) Cost of revenue, excluding amortization of intangible assets $ 1.1 Interest rate derivative contracts — Interest expense, net 5.9 Net investment hedges: Foreign currency-denominated debt (a) 0.8 N/A N/A Fiscal Nine Months Ended October 3, 2021 Cash flow hedges: Foreign currency forward contracts $ ( 3.7 ) Cost of revenue, excluding amortization of intangible assets $ 2.7 Interest rate derivative contracts ( 1.8 ) Interest expense, net 20.9 Net investment hedges: Foreign currency-denominated debt (a) 3.8 N/A N/A (a) The amount of loss (gain) recognized in OCI for the foreign-currency denominated debt is presented within the CTA component of OCI. These gains and losses will remain in CTA until the related hedged item affects earnings, which would occur upon disposal or complete or substantial liquidation of the underlying hedged entities. Designated Hedging Instruments Amount of loss Location of amounts Amount of loss Fiscal Quarter Ended September 27, 2020 Cash flow hedges: Foreign currency forward contracts $ 1.5 Cost of revenue, excluding amortization of intangible assets $ ( 2.0 ) Interest rate derivative contracts ( 0.5 ) Interest expense, net 0.5 Fiscal Nine Months Ended September 27, 2020 Cash flow hedges: Foreign currency forward contracts $ ( 2.2 ) Cost of revenue, excluding amortization of intangible assets $ ( 4.5 ) Interest rate derivative contracts (a) 47.1 Interest expense, net ( 1.9 ) (a) For the fiscal nine months ended September 27, 2020, the $ 47.1 million loss recognized in OCI for the interest rate derivative contracts does not include the $ 3.7 million loss from the cumulative effect of change in accounting standard, which is presented in Note 18.
Schedule of Designated Derivative Instruments within Interest Expense, Net and Cost of Revenue, Excluding Amortization of Intangible Assets in Statements of Operations	The following tables present the effect of the Company’s designated derivative instruments within Interest expense, net and Cost of revenue, excluding amortization of intangible assets in the unaudited consolidated statements of operations: Fiscal quarter ended October 3, 2021 Fiscal quarter ended September 27, 2020 Interest expense, net Cost of revenue, excluding amortization of intangible assets Interest expense, net Cost of revenue, excluding amortization of intangible assets Total amount of line item in unaudited consolidated statements of operations where effects of hedges are presented: $ 36.1 $ 252.4 $ 48.9 $ 234.1 Effects of cash flow hedging relationships Foreign currency forward contracts: Amount of loss (gain) reclassified from AOCI into income N/A 1.1 N/A ( 2.0 ) Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring N/A — N/A ( 0.1 ) Interest rate derivative contracts: Amount of net loss reclassified from AOCI into income 5.9 N/A 0.5 N/A Fiscal nine months ended October 3, 2021 Fiscal nine months ended September 27, 2020 Interest expense, net Cost of revenue, excluding amortization of intangible assets Interest expense, net Cost of revenue, excluding amortization of intangible assets Total amount of line item in unaudited consolidated statements of operations in which effects of hedges are presented: $ 112.5 $ 748.7 $ 148.6 $ 650.2 Effects of cash flow hedging relationships Foreign currency forward contracts: Amount of loss (gain) reclassified from AOCI into income N/A 2.7 N/A ( 4.5 ) Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring N/A — N/A ( 0.2 ) Interest rate derivative contracts: Amount of loss (gain) reclassified from AOCI into income 20.9 N/A ( 1.9 ) N/A Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring (a) 3.7 N/A — N/A (a) The amount is included within the total amount of loss (gain) reclassified from accumulated OCI into income.
Not Designated as Hedging Instrument
Schedule of Gains and Losses from Designated Derivative and Non-derivative Instruments	The following table presents mark-to-market (gains) and losses on non-designated derivatives recognized currently within the unaudited consolidated statements of operations: Location of amounts Fiscal Quarter Ended Fiscal Nine Months Ended Non-designated hedging instruments recognized in earnings on derivatives October 3, 2021 September 27, 2020 October 3, 2021 September 27, 2020 Interest rate derivative contracts Other expense, net $ 0.1 $ 0.4 $ — $ 1.3 Foreign currency forward contracts Other expense, net ( 1.6 ) 1.5 32.6 3.1 Cross-currency interest rate swap contracts Other expense, net — 2.5 ( 24.0 ) ( 2.6 )
Location and Fair Values of Designated and Non-Designated Hedging Instruments Recognized within Consolidated Balance Sheets	The following table presents the location and fair values of non-designated hedging instruments recognized within the unaudited consolidated balance sheets. The fair values of non-designated hedging instruments have been determined using Level 2 inputs. October 3, 2021 January 3, 2021 Interest rate derivative contracts: Accrued liabilities $ — $ 0.1 Other liabilities 6.8 11.1 Foreign currency forward contracts: Other current assets 1.7 0.3 Accrued liabilities 0.7 0.1 Cross currency interest rate swap contracts: Other current assets — 2.0 Other liabilities — 10.8
Designated as Hedging Instrument
Location and Fair Values of Designated and Non-Designated Hedging Instruments Recognized within Consolidated Balance Sheets	The following table presents the location and fair values of designated hedging instruments recognized within the unaudited consolidated balance sheets. The fair values of d esignated hedging instruments have been determined using Level 2 inputs. October 3, 2021 January 3, 2021 Interest rate derivative contracts: Accrued liabilities $ 0.1 $ 0.1 Other liabilities 25.4 44.1 Foreign currency forward contracts: Other current assets 3.8 4.2 Accrued liabilities 2.4 10.0

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Oct. 03, 2021
Equity [Abstract]
Summary of Accumulated Other Comprehensive Income (Loss), Net of Tax	The balances of accumulated other comprehensive income (loss), net of tax, were as follows for the fiscal quarter and nine months ended October 3, 2021 and September 27, 2020: Pension and Foreign Interest Unrealized Accumulated Balance at July 4,2021 $ ( 4.5 ) $ ( 0.6 ) $ ( 37.1 ) $ ( 12.8 ) $ ( 54.9 ) Current period deferrals — 1.0 — ( 13.9 ) ( 12.9 ) Amounts reclassified to net income — 1.1 5.9 — 7.0 Net change — 2.1 5.9 ( 13.9 ) ( 5.9 ) Balance at October 3, 2021 $ ( 4.5 ) $ 1.5 $ ( 31.2 ) $ ( 26.7 ) $ ( 61.0 ) Pension and Foreign Interest Unrealized Accumulated Balance at June 28, 2020 $ ( 4.3 ) $ 3.9 $ ( 55.8 ) $ ( 70.9 ) $ ( 127.1 ) Current period deferrals — ( 1.5 ) 0.5 8.1 7.1 Amounts reclassified to net loss — ( 2.0 ) 0.5 — ( 1.5 ) Net change — ( 3.5 ) 1.0 8.1 5.6 Balance at September 27, 2020 $ ( 4.3 ) $ 0.4 $ ( 54.8 ) $ ( 62.8 ) $ ( 121.5 ) Pension and Foreign Interest Unrealized Accumulated Balance at January 3, 2021 $ ( 4.5 ) $ ( 4.9 ) $ ( 53.9 ) $ ( 5.1 ) $ ( 68.4 ) Current period deferrals — 3.7 1.8 ( 21.7 ) ( 16.1 ) Amounts reclassified to net loss — 2.7 20.9 — 23.6 Net change — 6.4 22.7 ( 21.7 ) 7.5 Balance at October 3, 2021 $ ( 4.5 ) $ 1.5 $ ( 31.2 ) $ ( 26.7 ) $ ( 61.0 ) Pension and Foreign Interest Unrealized Accumulated Balance at December 29, 2019 $ ( 4.3 ) $ 2.7 $ ( 5.8 ) $ ( 64.5 ) $ ( 71.9 ) Current period deferrals — 2.2 ( 43.4 ) 1.7 ( 39.5 ) Amounts reclassified to net loss — ( 4.5 ) ( 1.9 ) — ( 6.4 ) Cumulative effect of change in accounting — — ( 3.7 ) — ( 3.7 ) Net change — ( 2.3 ) ( 49.0 ) 1.7 ( 49.6 ) Balance at September 27, 2020 $ ( 4.3 ) $ 0.4 $ ( 54.8 ) $ ( 62.8 ) $ ( 121.5 )

General and Description of th_2

General and Description of the Business - Additional Information (Details)	Feb. 05, 2021USD ($)	Sep. 30, 2021shares	Feb. 28, 2021USD ($)	Oct. 03, 2021USD ($)	Apr. 04, 2021USD ($)$ / sharesshares	Sep. 27, 2020USD ($)	Oct. 03, 2021USD ($)Countryshares	Sep. 27, 2020USD ($)	Sep. 30, 2022	Jan. 03, 2021USD ($)
General And Description Of Business [Line Items]
Net proceeds from IPO							$ 1,426,400,000	$ 0
Cash and cash equivalents				$ 255,900,000			255,900,000			$ 132,800,000
Accumulated deficit				(1,961,900,000)			(1,961,900,000)			$ (1,917,500,000)
Net loss				14,700,000		$ (28,500,000)	(44,400,000)	(171,000,000)
Cash provided by operating activities							188,200,000	(48,600,000)
Letters of credit issued				45,000,000			45,000,000
Selling, marketing and administrative expenses				$ 140,900,000		$ 121,000,000	$ 411,000,000	$ 347,900,000
Dollar Term Loan Facility
General And Description Of Business [Line Items]
Repayments of senior debt			$ 892,700,000
Revolving Credit Facility
General And Description Of Business [Line Items]
Basis point step-downs of first lien net leverage ratio				0.50			0.50
Maximum percentage of committed amount for first lien net leverage ratio							30.00%
Outstanding borrowings				$ 0			$ 0
Revolving Credit Facility | Scenario Forecast
General And Description Of Business [Line Items]
Basis point step-downs of first lien net leverage ratio									0.50
2025 Notes
General And Description Of Business [Line Items]
Repayment of debt	$ 160,000,000
Redemption premium	11,800,000
2028 Notes
General And Description Of Business [Line Items]
Repayment of debt	270,000,000
Redemption premium	$ 19,600,000
Secondary Public Offering
General And Description Of Business [Line Items]
Selling, marketing and administrative expenses				$ 1,100,000			$ 1,100,000
Minimum
General And Description Of Business [Line Items]
Number of countries and territories with commercial presence | Country							130
Number of countries with direct commercial presence | Country							30
Maximum | Revolving Credit Facility
General And Description Of Business [Line Items]
First lien net leverage ratio				5.5			5.5
Ortho-Clinical Diagnostics Holdings Luxembourg S.à r.l | UK Holdco
General And Description Of Business [Line Items]
Ownership interest				100.00%			100.00%
Ortho-Clinical Diagnostics S.A. | UK Holdco
General And Description Of Business [Line Items]
Ownership interest				100.00%			100.00%
Common Stock
General And Description Of Business [Line Items]
Initial share capital | shares							1
Ordinary shares issued and sold | shares							87,400,000
Net proceeds from IPO					$ 1,426,400,000
Common Stock | IPO
General And Description Of Business [Line Items]
Ordinary shares, price per share | $ / shares					$ 17
Ordinary shares issued and sold | shares					87,400,000
Common Stock | Underwriters Option
General And Description Of Business [Line Items]
Initial share capital | shares		3,300,000
Ordinary shares issued and sold | shares					11,400,000
Common Stock | Secondary Public Offering
General And Description Of Business [Line Items]
Ordinary shares issued and sold | shares		25,300,000
Preferred Redeemable Shares
General And Description Of Business [Line Items]
Initial share capital | shares							50,000

Basis of Presentation of the _2

Basis of Presentation of the Unaudited Consolidated Financial Statements - Additional Information (Details)	Jan. 18, 2021shares
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Stock issued during period, shares, stock splits	54,860,691
Additional share for each existing share	0.5934
Stock split conversion ratio	1.5934

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Details) - ASU 2019-12	Oct. 03, 2021
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 4, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Schedule of weighted-average number of ordinary shares used in computation of basic and diluted net income (loss) per share (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Earnings Per Share [Abstract]
Basic weighted-average ordinary shares outstanding	235.6	146.4	225.4	146.4
Effect of stock options, unvested restricted shares and restricted stock units	7.2	0	0	0
Diluted weighted-average ordinary shares outstanding	242.8	146.4	225.4	146.4

Net Income (Loss) Per Share -_2

Net Income (Loss) Per Share - Summary of total outstanding ordinary share equivalents, unaffected by treasury stock method weighted-average calculation (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
OutstandingOrdinaryShareEquivalentsUnaffectedByTheTreasuryStockMethodWeightedAverageCalculationLineItem
Stock options	13.9	16.2	13.9	16.2
Unvested restricted shares and restricted stock units	0.6	0.3	0.6	0.3
Total	14.5	16.5	14.5	16.5

Revenue - Additional Informatio

Revenue - Additional Information (Details)	3 Months Ended		9 Months Ended
	Oct. 03, 2021USD ($)	Sep. 27, 2020USD ($)AgreementAward	Oct. 03, 2021USD ($)	Sep. 27, 2020USD ($)	Apr. 16, 2021USD ($)	Jan. 03, 2021USD ($)
Disaggregation Of Revenue [Line Items]
Contract asset	$ 48,700,000		$ 48,700,000			$ 42,800,000
Credit losses related to contract assets	0	$ 0	0	$ 0
Deferred revenue, current	32,600,000		32,600,000			35,500,000
Deferred revenue, revenue recognized			31,300,000
Award received in connection with arbitration proceeding	8,500,000
Revenue recognized	15,100,000	$ 7,000,000	27,800,000	14,700,000
Other Assets
Disaggregation Of Revenue [Line Items]
Contract asset	800,000		800,000			2,400,000
Other Liabilities
Disaggregation Of Revenue [Line Items]
Deferred revenue, non-current	5,800,000		5,800,000			6,600,000
Customer Supply Agreement
Disaggregation Of Revenue [Line Items]
Contract asset	12,700,000		12,700,000			15,100,000
Customer Supply Agreement | Other Assets
Disaggregation Of Revenue [Line Items]
Contract asset	800,000		800,000			2,400,000
Contractual Arrangements
Disaggregation Of Revenue [Line Items]
Contract asset	36,000,000		36,000,000			24,300,000
Contract Manufacturing Agreements
Disaggregation Of Revenue [Line Items]
Contract asset						$ 3,400,000
Biomedical Advanced Research and Development Authority
Disaggregation Of Revenue [Line Items]
Number of collaboration and license agreements | Agreement		2
Number of awards under collaboration and license agreements | Award		2
Biomedical Advanced Research and Development Authority | Maximum
Disaggregation Of Revenue [Line Items]
Potential payment receivable for development and submission of emergency use authorizations and 510(k) applications of COVID-19 tests		$ 13,600,000		13,600,000
Additional awards granted, potential payment receivable for development and submission of emergency use authorizations and 510(k) applications of COVID-19 tests					$ 3,600,000
Biomedical Advanced Research and Development Authority | Grant Revenue
Disaggregation Of Revenue [Line Items]
Revenue recognized	$ 1,500,000	$ 2,500,000	$ 7,300,000	$ 2,500,000

Revenue - Schedule of Balance o

Revenue - Schedule of Balance of Contract Assets Recorded in Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Disaggregation Of Revenue [Line Items]
Total contract assets	$ 48.7	$ 42.8
Other Current Assets
Disaggregation Of Revenue [Line Items]
Total contract assets	47.8	40.4
Other Assets
Disaggregation Of Revenue [Line Items]
Total contract assets	$ 0.8	$ 2.4

Revenue - Summary of Net Revenu

Revenue - Summary of Net Revenue by Line of Business (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Disaggregation Of Revenue [Line Items]
Total Product Revenue	$ 507.4	$ 444.1	$ 1,494.1	$ 1,234.9
Collaborations and Other Revenue	15.1	7	27.8	14.7
Net Revenue	522.5	451.1	1,521.8	1,249.6
Clinical Laboratories
Disaggregation Of Revenue [Line Items]
Total Product Revenue	336.6	300.1	993.9	816.7
Transfusion Medicine
Disaggregation Of Revenue [Line Items]
Total Product Revenue	170.7	140.6	494.5	414.5
Other Product Revenue
Disaggregation Of Revenue [Line Items]
Total Product Revenue	$ 0	$ 3.3	$ 5.6	$ 3.7

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 71.5	$ 77.2
Goods in process	38.3	35.2
Finished goods	198.6	166.3
Total Inventories	$ 308.3	$ 278.7

Borrowings and Other Arrangem_3

Borrowings and Other Arrangements - Components of Borrowings (Details) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Debt Instrument [Line Items]
Finance lease obligation	$ 0.8	$ 1
Other short-term borrowings	0.8	0.9
Other long-term borrowings	2.9	3.9
Unamortized deferred financing costs	(22.6)	(40.9)
Unamortized original issue discount	(5.6)	(11.3)
Total borrowings	2,271.3	3,718.5
Less: Current portion	(64.4)	(160)
Long-term borrowings	2,206.9	3,558.5
Dollar Term Loan Facility
Debt Instrument [Line Items]
Long-term borrowings, gross	1,292.8	2,185.5
Unamortized deferred financing costs	(8.6)	(17.3)
Euro Term Loan Facility
Debt Instrument [Line Items]
Long-term borrowings, gross	357.2	408.9
Unamortized deferred financing costs	(3.8)	(4.6)
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term borrowings, gross	0	0
Unamortized deferred financing costs	(3.1)	(3.4)
2028 Notes
Debt Instrument [Line Items]
Long-term borrowings, gross	405	675
Unamortized deferred financing costs	(6.6)	(11.8)
2025 Notes
Debt Instrument [Line Items]
Long-term borrowings, gross	240	400
Unamortized deferred financing costs	(3.6)	(7)
Accounts Receivable Financing
Debt Instrument [Line Items]
Long-term borrowings, gross	0	75
Sale and Leaseback Financing
Debt Instrument [Line Items]
Long-term borrowings, gross	$ 0	$ 20.5

Borrowings and Other Arrangem_4

Borrowings and Other Arrangements - Senior Secured Credit Facilities - Additional Information (Details)	Feb. 05, 2021USD ($)	Feb. 28, 2021USD ($)	Oct. 03, 2021USD ($)	Sep. 27, 2020USD ($)	Oct. 03, 2021USD ($)	Sep. 27, 2020USD ($)	Feb. 05, 2021EUR (€)	Jan. 03, 2021USD ($)
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ 0	$ 50,300,000	$ 12,600,000
Letters Of Credit Outstanding Amount			45,000,000		45,000,000
Unamortized deferred financing costs			22,600,000		22,600,000			$ 40,900,000
Euro Term Loan Facility
Debt Instrument [Line Items]
Unamortized deferred financing costs			$ 3,800,000		$ 3,800,000			4,600,000
Debt instrument, effective interest rate			3.88%		3.88%
Revolving Credit Facility
Debt Instrument [Line Items]
Outstanding borrowings			$ 0		$ 0
Line of credit, available borrowing capacity			455,000,000		$ 455,000,000
Maximum percentage of committed amount for first lien net leverage ratio					30.00%
Unamortized deferred financing costs			$ 3,100,000		$ 3,100,000			3,400,000
Revolving Credit Facility | Each Fiscal Quarter Ending on or Prior to September 30, 2022
Debt Instrument [Line Items]
First lien net leverage ratio			5.50		5.50
Revolving Credit Facility | Each Fiscal Quarter Ending Thereafter
Debt Instrument [Line Items]
First lien net leverage ratio			5		5
Dollar Term Loan Facility
Debt Instrument [Line Items]
Early repayment of debt		$ 892,700,000
Unamortized deferred financing costs			$ 8,600,000		$ 8,600,000			$ 17,300,000
Debt instrument, effective interest rate			5.76%		5.76%
Dollar Term Loan Facility | Other Expense, Net
Debt Instrument [Line Items]
Loss on extinguishment of debt					$ (11,400,000)
Letters of Credit
Debt Instrument [Line Items]
Letters Of Credit Outstanding Amount			$ 45,000,000		$ 45,000,000
Senior Secured Credit Facilities
Debt Instrument [Line Items]
Basis point step-downs on interest rate of first lien net leverage ratio			0.50%		0.50%
Fifth Amendment of Credit Agreement | Euro Term Loan Facility
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity | €							€ 337,400,000
Fifth Amendment of Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity	$ 500,000,000
Line of credit, increase in borrowing capacity	$ 150,000,000
Debt instrument, maturity date	Feb. 5, 2026

Borrowings and Other Arrangem_5

Borrowings and Other Arrangements - 2025 Notes - Additional Information (Details) - USD ($)	Feb. 05, 2021	Jun. 11, 2020	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020	Jan. 03, 2021
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ 0	$ (50,300,000)	$ (12,600,000)
Unamortized deferred financing costs			22,600,000		$ 22,600,000		$ 40,900,000
2025 Notes
Debt Instrument [Line Items]
Aggregate principal amount		$ 400,000,000
Debt instrument, stated interest rate		7.375%
Debt instrument, maturity date		Jun. 1, 2025
Deferred financing costs, gross		$ 7,500,000
Debt instrument, redemption period start date					Jun. 1, 2022
Redemption price percentage		107.375%
Percentage of principal amount of debt with net cash proceeds of equity offerings		40.00%
Repayment of debt	$ 160,000,000
Redemption premium	11,800,000
Loss on extinguishment of debt	(14,500,000)
Write off of deferred debt Issuance cost	2,700,000
Unamortized deferred financing costs			$ 3,600,000		$ 3,600,000		$ 7,000,000
Debt instrument, effective interest rate			8.03%		8.03%
2025 Notes | Other Expense, Net
Debt Instrument [Line Items]
Redemption premium	$ 11,800,000				$ 11,800,000
2025 Notes | Prior to June 1, 2022
Debt Instrument [Line Items]
Redemption price percentage		100.00%

Borrowings and Other Arrangem_6

Borrowings and Other Arrangements - Schedule of Redemption Prices of 2025 Notes Expressed as Percentages of Principal Amount (Details) - 2025 Notes	Jun. 11, 2020	Oct. 03, 2021
Debt Instrument [Line Items]
Redemption price percentage	107.375%
2022
Debt Instrument [Line Items]
Redemption price percentage		103.688%
2023
Debt Instrument [Line Items]
Redemption price percentage		101.844%
2024 and Thereafter
Debt Instrument [Line Items]
Redemption price percentage		100.00%

Borrowings and Other Arrangem_7

Borrowings and Other Arrangements - 2028 Notes - Additional Information (Details) - USD ($)	Feb. 05, 2021	Jan. 27, 2020	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020	Jan. 03, 2021
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ 0	$ (50,300,000)	$ (12,600,000)
Unamortized deferred financing costs			22,600,000		$ 22,600,000		$ 40,900,000
2028 Notes
Debt Instrument [Line Items]
Aggregate principal amount		$ 675,000,000
Debt instrument, stated interest rate		7.25%
Debt instrument, maturity date		Feb. 1, 2028
Deferred financing costs, gross		$ 12,900,000
Debt instrument, redemption period start date					Feb. 1, 2023
Redemption price percentage		107.25%
Percentage of principal amount of debt with net cash proceeds of equity offerings		40.00%
Repayment of debt	$ 270,000,000
Redemption premium	19,600,000
Loss on extinguishment of debt	(24,300,000)
Write off of deferred debt Issuance cost	4,700,000
Unamortized deferred financing costs			$ 6,600,000		$ 6,600,000		$ 11,800,000
Debt instrument, effective interest rate			7.76%		7.76%
2028 Notes | Other Expense, Net
Debt Instrument [Line Items]
Redemption premium	$ 19,600,000				$ 19,600,000
2028 Notes | Prior to February 1, 2023
Debt Instrument [Line Items]
Redemption price percentage		100.00%

Borrowings and Other Arrangem_8

Borrowings and Other Arrangements - Schedule of Redemption Prices of 2028 Notes Expressed as Percentages of Principal Amount (Details) - 2028 Notes	Jan. 27, 2020	Oct. 03, 2021
Debt Instrument [Line Items]
Redemption price percentage	107.25%
2023
Debt Instrument [Line Items]
Redemption price percentage		103.625%
2024
Debt Instrument [Line Items]
Redemption price percentage		101.813%
2025 and Thereafter
Debt Instrument [Line Items]
Redemption price percentage		100.00%

Borrowings and Other Arrangem_9

Borrowings and Other Arrangements - 2022 Notes - Additional Information (Details) - USD ($) $ in Millions	Jun. 12, 2020	Jan. 28, 2020	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ 0	$ (50.3)	$ (12.6)
2022 Notes
Debt Instrument [Line Items]
Long-term borrowings, outstanding balance		$ 1,300
Repayment of debt	$ 300	$ 1,000
Debt instrument, stated interest rate		6.625%
Loss on extinguishment of debt						$ (12.6)

Borrowings and Other Arrange_10

Borrowings and Other Arrangements - Sale and Leaseback Financing - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Jun. 30, 2016	Oct. 03, 2021	Jan. 03, 2021
Debt Disclosure [Abstract]
Sale And Leaseback Financing Assets Sold	$ 36.3
Initial term		two years
Monthly rental payments	1.5
Security deposit			$ 9.1
Financing period		42 months
Financing obligation	$ 36.3

Borrowings and Other Arrange_11

Borrowings and Other Arrangements - Accounts Receivable Financing - Additional Information (Details) - Financing Program $ in Millions	9 Months Ended
	Oct. 03, 2021USD ($)
Debt Instrument [Line Items]
Debt instrument, maturity date	Jan. 24, 2022
Percentage of Debt Borrowing Base Rate on Account Receivable	85.00%
Receivables Purchase Agreement
Debt Instrument [Line Items]
Debt instrument, maturity date	Jun. 11, 2024
Maximum amount of receivable to be sold	$ 75
Debt instrument, maturity date, description	The RPA has a scheduled termination date which is the earlier of (i) June 11, 2024, and (ii) the date that is 90 days prior to the maturity of the indebtedness incurred under the Company’s Senior Secured Credit Facilities.
Receivables Purchase Agreement | Each Fiscal Quarter Ending after June 30, 2021 and on or Prior to September 30, 2022
Debt Instrument [Line Items]
First lien net leverage ratio	5.50
Receivables Purchase Agreement | Each Fiscal Quarter Ending Thereafter
Debt Instrument [Line Items]
First lien net leverage ratio	5
LIBOR Floor Rate
Debt Instrument [Line Items]
Debt instrument, variable percentage rate	0.00%
LIBOR Rate
Debt Instrument [Line Items]
Debt instrument, variable percentage rate	2.25%
Base Rate
Debt Instrument [Line Items]
Debt instrument, variable percentage rate	1.25%
Maximum
Debt Instrument [Line Items]
Debt Instrument Face Amount	$ 75

Borrowings and Other Arrange_12

Borrowings and Other Arrangements - Schedule of Interest Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Amortization of:
Deferred financing costs	$ 1.6	$ 2.2	$ 4.9	$ 6.5
Original issue discount	0.4	0.6	1.1	1.8
Derivative instruments and other	7.6	2.8	20.7	(0.1)
Interest expense, net	36.1	48.9	112.5	148.6
2028 Notes
Interest expense
Interest expense	7.3	12.1	23.7	32.8
2025 Notes
Interest expense
Interest expense	4.4	7.3	14.3	8.8
2022 Notes
Interest expense
Interest expense	0	0	0	14.1
Accounts Receivable Financing
Interest expense
Interest expense	0	1.1	0.7	3.7
Revolving Credit Facility
Interest expense
Interest expense	1.5	0.2	2.1	3.4
Dollar Term Loan Facility
Interest expense
Interest expense	10.2	19.1	34.8	68.6
Euro Term Loan Facility
Interest expense
Interest expense	$ 3.3	$ 3.5	$ 10.3	$ 9

Borrowings and Other Arrange_13

Borrowings and Other Arrangements - Schedule of Required Future Repayments of all Borrowings Outstanding (Details) $ in Millions	Oct. 03, 2021USD ($)
Debt Disclosure [Abstract]
Remainder of 2021	$ 45.8
2022	63.5
2023	63.1
2024	62.8
2025	1,659.4
Thereafter	405
Total	$ 2,299.5

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021	Sep. 27, 2020	Dec. 29, 2019
Supplemental Balance Sheet Information [Abstract]
Cash and cash equivalents	$ 255.9	$ 132.8
Restricted cash included in Other assets	1.8	11.4
Cash, cash equivalents and restricted cash	$ 257.7	$ 144.2	$ 79.7	$ 84

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Schedule of Accrued Liabilities (Details) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Supplemental Balance Sheet Information [Abstract]
Accrued compensation and employee-related obligations	$ 101.8	$ 110.5
Accrued commissions and rebates	28.3	24.9
Accrued taxes other than income	18.7	14.3
Accrued interest	17.3	42.2
Current portion of operating lease liabilities	12	15.1
Derivatives	3.2	10.3
Other accrued liabilities	70.3	67.4
Total accrued liabilities	$ 251.5	$ 284.7

Collaborations and Other Rela_2

Collaborations and Other Relationships - Additional Information (Details) - USD ($) $ in Millions	Sep. 04, 2020	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020	Jan. 03, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment		$ 0	$ 7.5	$ 0	$ 7.5
Research and development expense		32.1	32.7	91.3	82.1
Accounts payable related to purchases		139.3		139.3		$ 146.2
Quotient Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sales to Quotient		0.1	0.1	0.1	0.2
Joint Business | Grifols Diagnostic Solutions, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Net profit shared under joint venture, before tax		21.3	13.4	45.5	35.9
Letter Agreement | Quotient Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment	$ 7.5
Research and development expense			7.5		7.5
Inventories, purchased		5.1	$ 6.4	17.1	$ 17.1
Accounts payable related to purchases		$ 2.9		$ 2.9		$ 2.3
Letter Agreement | Quotient Limited | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential additional payments upon achievement of certain regulatory milestones and commercial sales benchmarks	60
Potential payments upon achievement of certain cumulative revenue milestones	$ 25

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020	Jan. 03, 2021
Income Tax [Line Items]
Income (Loss) incurred before provision for income taxes	$ 20.7	$ (38.8)	$ (20)	$ (173.4)
Provision for income taxes	$ 6	$ (10.3)	$ 24.4	$ (2.4)
Effective tax rate	29.10%	26.50%	(122.20%)	1.40%
Net Cost Impact Due To Valuation Allowances	$ 27.5	$ 39	$ 27.5	$ 39
Net Benefit Due to Increase In Interest Expenses	10.9			12
Net Cost Due to Tax Rate Difference	10.6			$ 9.7
Unrecognized tax benefits	28.3		28.3
Unrecognized tax benefits that would affect effective income tax rate	23.8		23.8
Accrued interest and penalties	6.7		6.7
Johnson and Johnson
Income Tax [Line Items]
Indemnification receivable	17.6		17.6		$ 17
Interest and penalties	$ 0.2		$ 0.6

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Under Statements Of Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 5.1	$ 2.4	$ 19.6	$ 6.2
Cost of revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	0.1	0.2	0.4	0.6
Selling, marketing and administrative expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	4.9	2.1	18.9	5.4
Research and development expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 0.1	$ 0.1	$ 0.4	$ 0.2

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Millions	May 03, 2021	Oct. 03, 2021	Jul. 04, 2021	Oct. 03, 2021
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, vesting period	3 years
Additional stock-based compensation expense		$ 0.3		$ 1.6
Remaining percentage of vesting award				50.00%
Additional shares granted				0
Compensation cost relating to nonvested shares not yet recognized		$ 0.7		$ 0.7
Unrecognized expense recognized period				1 year
Liquidity Event Option Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional stock-based compensation expense			$ 4.6
IPO | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of vesting award accelerated	50.00%

Segment and Geographic Inform_3

Segment and Geographic Information - Additional Information (Detail) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021USD ($)	Sep. 27, 2020USD ($)	Oct. 03, 2021USD ($)Segment	Sep. 27, 2020USD ($)
Segment Reporting [Abstract]
Number of reportable segments | Segment			3
Net unrealized gains of foreign currency transaction | $	$ (4.3)	$ (3.9)	$ (38)	$ (51.1)

Segment and Geographic Inform_4

Segment and Geographic Information - Net Revenue by Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Segment Reporting Information [Line Items]
Revenue recognized	$ 522.5	$ 451.1	$ 1,521.8	$ 1,249.6
Other
Segment Reporting Information [Line Items]
Revenue recognized	63.2	55.6	195.1	163.2
Reportable Segment
Segment Reporting Information [Line Items]
Revenue recognized	459.3	395.5	1,326.8	1,086.3
Reportable Segment | Americas
Segment Reporting Information [Line Items]
Revenue recognized	306.5	264.2	924.2	755.8
Reportable Segment | EMEA
Segment Reporting Information [Line Items]
Revenue recognized	67.2	58.6	203.5	168.2
Reportable Segment | Greater China
Segment Reporting Information [Line Items]
Revenue recognized	$ 85.6	$ 72.7	$ 199.1	$ 162.3

Segment and Geographic Inform_5

Segment and Geographic Information - Adjusted EBITDA by Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Segment Reporting Information [Line Items]
Adjusted EBITDA	$ 139.6	$ 119.5	$ 420.1	$ 322.4
Operating Segments | Americas
Segment Reporting Information [Line Items]
Adjusted EBITDA	125	116.8	394.2	329.9
Operating Segments | EMEA
Segment Reporting Information [Line Items]
Adjusted EBITDA	17.2	10.7	47.7	31.4
Operating Segments | Greater China
Segment Reporting Information [Line Items]
Adjusted EBITDA	42.2	41.1	91.7	78.9
Operating Segments | Other
Segment Reporting Information [Line Items]
Adjusted EBITDA	19	16.7	61.4	49.9
Corporate
Segment Reporting Information [Line Items]
Adjusted EBITDA	$ (63.8)	$ (65.9)	$ (174.8)	$ (167.8)

Segment and Geographic Inform_6

Segment and Geographic Information - Reconciliation of Net Loss to Adjusted EBITDA (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Segment Reporting Information [Line Items]
Net loss	$ 14.7	$ (28.5)	$ (44.4)	$ (171)
Interest expense, net	36.1	48.9	112.5	148.6
Provision for (benefit from) income taxes	6	(10.3)	24.4	(2.4)
Depreciation and amortization	80.8	79.9	246.6	239.6
Stock-based compensation			19.6	6.2
Restructuring and severance-related costs	1.7	4.7	4.7	9.3
Arbitration award	(7.4)	0	(7.4)	0
Tax indemnification (income) expense, net	(0.2)	16.5	(0.6)	11.6
Loss on extinguishment of debt	0	0	50.3	12.6
Quotient upfront payment	0	7.5	0	7.5
Unrealized foreign currency exchange (gains) losses, net	0	6.3	0	(46)
Other adjustments	2.9	4.7	14.5	14.4
Adjusted EBITDA	139.6	119.5	420.1	322.4
2014 Plan [Member]
Segment Reporting Information [Line Items]
Stock-based compensation	$ 5	$ 2.4	$ 19.5	$ 6.2

Noncash Investing and Financi_2

Noncash Investing and Financing Activities - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Jan. 03, 2021	Dec. 29, 2019
Noncash Investing And Financing Items [Abstract]
Noncash transfer of inventory to property, plant and equipment, net	$ 82.6	$ 91.5
Purchases of property, plant and equipment and capitalized internal-use software costs included in Accounts payable and Accrued liabilities	10.4	$ 3.5	$ 11.4	$ 14.1
Initial public offering costs included in Accounts payable and Accrued liabilities	$ 0		$ 3

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020	Jan. 03, 2021
Related Party Transaction [Line Items]
Revenue recognized	$ 522.5	$ 451.1	$ 1,521.8	$ 1,249.6
Carlyle Investment Management, L.L.C. | Healthcare Equipment Company
Related Party Transaction [Line Items]
Inventories, purchased	1.3	0	2.2	0
Due to related party					$ 0
Carlyle Investment Management, L.L.C. | Health Care Diagnostics Companies
Related Party Transaction [Line Items]
Revenue recognized	3.2	0.4	5	1.3
Due to related party	1.2		1.2		1.2
Carlyle Investment Management, L.L.C. | Security Services Company
Related Party Transaction [Line Items]
Due to related party	0.1		0.1		0.1
Security service expense	0.2		0.8
Carlyle Investment Management, L.L.C. | Information Technology Company
Related Party Transaction [Line Items]
IT service fees	0.3	0.2	1	0.2
Due to related party	0.1		0.1		0.1
Carlyle Investment Management, L.L.C. | Consulting Services Company
Related Party Transaction [Line Items]
Consulting fees	0.1	0.3	1.3	0.7
Due to related party	0		0		0.3
Carlyle Investment Management, L.L.C. | Pharmacy Benefit Management
Related Party Transaction [Line Items]
Pharmacy related services, fees	1.5	1.6	4.4	4.6
Due to related party	0.4		$ 0.4		$ 0.6
Carlyle Investment Management, L.L.C. | Consulting Services Agreement
Related Party Transaction [Line Items]
Agreement, initial term			10 years
Annual management fee			$ 3
Management fee and other out-of-pocket expenses	$ 0.8	$ 0.8	$ 2.3	$ 2.3

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Values of Long-term Borrowings (Details) - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Dollar Term Loan Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term borrowings, fair value	$ 1,496.8	$ 2,627.7
Euro Term Loan Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term borrowings, fair value	357.1	401.1
2028 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term borrowings, fair value	434.4	710.4
2025 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term borrowings, fair value	$ 252	$ 424

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Details) € in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021USD ($)	Apr. 04, 2021USD ($)	Oct. 03, 2021USD ($)	Oct. 03, 2021EUR (€)	Jan. 03, 2021USD ($)	Sep. 29, 2019
Derivative [Line Items]
Pre-tax unrealized loss within OCI to be reclassified to earnings in next 12 months, interest rate derivative instruments	$ 16,200,000		$ 16,200,000
Pre-tax unrealized gain within OCI to be reclassified to earnings in next 12 months, foreign currency contracts	1,600,000		1,600,000
Euro Term Loan Facility
Derivative [Line Items]
Net investment in a foreign operation, designated as economic hedge	301,500,000		301,500,000	€ 260
Interest Rate Swap
Derivative [Line Items]
Interest rate cap amount						3.50%
Derivative loss included in AOCI	6,700,000		6,700,000		$ 9,800,000
Deferred losses released to interest expense	900,000	$ 600,000	2,600,000
Interest Rate Swap Previously Hedged
Derivative [Line Items]
Derivative loss included in AOCI	24,500,000		24,500,000
Deferred losses released to interest expense		$ 3,100,000
Japanese Yen Cross Currency Swap
Derivative [Line Items]
Derivative notional amount	$ 350,000,000		$ 350,000,000
Weighted average interest rate	5.56%		5.56%	5.56%
Derivative instrument term			5 years
U.S. Dollar to Japanese Yen Cross Currency Swaps | 2028 Notes
Derivative [Line Items]
Net settlement on derivatives			$ 12,800,000

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Schedule of Interest Rate Derivative Agreements (Details)	9 Months Ended
	Oct. 03, 2021USD ($)
Cash Flow Hedge
Derivative [Line Items]
Effective date	Sep. 27, 2019
Expiration date	Dec. 31, 2023
Interest rate cap amount	1.635%
Derivative notional amount	$ 1,500,000,000
Floating rate	1-month LIBOR rate
Not Designated as Hedging Instrument | Interest Rate Swap 1
Derivative [Line Items]
Effective date	Dec. 31, 2020
Expiration date	Dec. 31, 2023
Interest rate cap amount	3.50%
Derivative notional amount	$ 1,500,000,000

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Schedule of Interest Rate Derivative Agreements (Parenthetical) (Details) - Cash Flow Hedge	Oct. 03, 2021USD ($)
Derivative [Line Items]
Derivative notional amount	$ 1,500,000,000
Expected Notional Value 2022
Derivative [Line Items]
Derivative notional amount	1,000,000,000
Expected Notional Value 2023
Derivative [Line Items]
Derivative notional amount	$ 500,000,000

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Schedule of Currency Hedging Instruments Outstanding (Details)	Oct. 03, 2021USD ($)
Cash Flow Hedge
Derivative [Line Items]
Derivative notional amount	$ 1,500,000,000
Foreign Currency Derivatives | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative notional amount	262,200,000
Foreign Currency Derivatives | Cash Flow Hedge | Designated as Hedging Instrument
Derivative [Line Items]
Derivative notional amount	$ 161,500,000

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Schedule of Gains and Losses from Designated Derivative and Non-derivative Instruments within AOCI (Details) - Designated as Hedging Instrument - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Cash Flow Hedge | Cost of Revenue Excluding Amortization of Intangible Assets | Foreign Currency Derivatives
Derivative [Line Items]
Amount of loss (gain) recognized in OCI on hedges	$ (1)	$ 1.5	$ (3.7)	$ (2.2)
Amount of net loss (gain) reclassified from AOCI into income	1.1	(2)	2.7	(4.5)
Cash Flow Hedge | Interest Expense, Net | Interest Rate Derivatives
Derivative [Line Items]
Amount of loss (gain) recognized in OCI on hedges	0	(0.5)	(1.8)	47.1
Amount of net loss (gain) reclassified from AOCI into income	5.9	$ 0.5	20.9	$ (1.9)
Net Investment Hedge | Foreign currency-Denominated Debt
Derivative [Line Items]
Amount of loss (gain) recognized in OCI on hedges	$ 0.8		$ 3.8

Derivative Instruments and He_8

Derivative Instruments and Hedging Activities - Schedule of Gains and Losses from Designated Derivative and Non-derivative Instruments within AOCI (Parenthetical) (Details) - Cash Flow Hedge - Designated as Hedging Instrument - Interest Expense, Net - Interest Rate Derivatives - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Derivative [Line Items]
Amount of loss (gain) recognized in OCI on hedges	$ 0	$ (0.5)	$ (1.8)	$ 47.1
Loss from cumulative effect of change in accounting standard				$ 3.7

Derivative Instruments and He_9

Derivative Instruments and Hedging Activities - Schedule of Designated Derivative Instruments within Interest Expense, Net and Cost of Revenue, Excluding Amortization of Intangible Assets in Statements of Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Derivative [Line Items]
Interest expense, net	$ 36.1	$ 48.9	$ 112.5	$ 148.6
Cost of revenue, excluding amortization of intangible assets	252.4	234.1	748.7	650.2
Cash Flow Hedge
Derivative [Line Items]
Interest expense, net	36.1	48.9	112.5	148.6
Cost of revenue, excluding amortization of intangible assets	252.4	234.1	748.7	650.2
Cash Flow Hedge | Interest Expense, Net | Designated as Hedging Instrument | Interest Rate Derivatives
Derivative [Line Items]
Amount of net loss (gain) reclassified from AOCI into income	5.9	0.5	20.9	(1.9)
Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring			3.7	0
Cash Flow Hedge | Cost of Revenue Excluding Amortization of Intangible Assets | Designated as Hedging Instrument | Foreign Currency Derivatives
Derivative [Line Items]
Amount of net loss (gain) reclassified from AOCI into income	1.1	(2)	2.7	(4.5)
Amount reclassified from AOCI into income due to forecast transaction that is no longer probable of occurring	$ 0	$ (0.1)	$ 0	$ (0.2)

Derivative Instruments and H_10

Derivative Instruments and Hedging Activities - Schedule of Mark-to-Market (Gains) and Losses on Non-Designated Derivatives Recognized (Details) - Other Expense, Net - Not Designated as Hedging Instrument - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Derivative [Line Items]
Interest rate derivative contracts	$ 0.1	$ 0.4	$ 0	$ 1.3
Foreign currency forward contracts	(1.6)	1.5	32.6	3.1
Cross currency interest rate swap contracts	$ 0	$ 2.5	$ (24)	$ (2.6)

Derivative Instruments and H_11

Derivative Instruments and Hedging Activities - Location and Fair Values of Designated Hedging Instruments Recognized within Consolidated Balance Sheets (Details) - Level 2 - Cash Flow Hedge - Designated as Hedging Instrument - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Accrued Liabilities
Derivative [Line Items]
Interest rate derivative contracts	$ 0.1	$ 0.1
Foreign currency forward contracts	2.4	10
Other Liabilities
Derivative [Line Items]
Interest rate derivative contracts	25.4	44.1
Other Current Assets
Derivative [Line Items]
Foreign currency forward contracts	$ 3.8	$ 4.2

Derivative Instruments and H_12

Derivative Instruments and Hedging Activities - Location and Fair Values of Non-Designated Hedging Instruments Recognized within Consolidated Balance Sheets (Details) - Level 2 - Cash Flow Hedge - Not Designated as Hedging Instrument - USD ($) $ in Millions	Oct. 03, 2021	Jan. 03, 2021
Accrued Liabilities
Derivative [Line Items]
Interest rate derivative contracts	$ 0	$ 0.1
Foreign currency forward contracts	0.7	0.1
Other Liabilities
Derivative [Line Items]
Interest rate derivative contracts	6.8	11.1
Cross currency interest rate swap contracts	0	10.8
Other Current Assets
Derivative [Line Items]
Foreign currency forward contracts	1.7	0.3
Cross currency interest rate swap contracts	$ 0	$ 2

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Summary of Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 375.6	$ (1,006.5)	$ (1,010.8)	$ (812.8)
Other comprehensive income (loss), net of tax	(5.9)	5.6	7.5	(49.6)
Ending balance	396.9	(1,027)	396.9	(1,027)
Pension and Other Postemployment Benefits
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(4.5)	(4.3)	(4.5)	(4.3)
Current period deferrals	0	0	0	0
Amounts reclassified to net income (loss)	0	0	0	0
Cumulative effect of change in accounting standard				0
Other comprehensive income (loss), net of tax	0	0	0	0
Ending balance	(4.5)	(4.3)	(4.5)	(4.3)
Derivatives | Foreign Currency Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(0.6)	3.9	(4.9)	2.7
Current period deferrals	1	(1.5)	3.7	2.2
Amounts reclassified to net income (loss)	1.1	(2)	2.7	(4.5)
Cumulative effect of change in accounting standard				0
Other comprehensive income (loss), net of tax	2.1	(3.5)	6.4	(2.3)
Ending balance	1.5	0.4	1.5	0.4
Derivatives | Interest Rate Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(37.1)	(55.8)	(53.9)	(5.8)
Current period deferrals	0	0.5	1.8	(43.4)
Amounts reclassified to net income (loss)	5.9	0.5	20.9	(1.9)
Cumulative effect of change in accounting standard				(3.7)
Other comprehensive income (loss), net of tax	5.9	1	22.7	(49)
Ending balance	(31.2)	(54.8)	(31.2)	(54.8)
Unrealized Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(12.8)	(70.9)	(5.1)	(64.5)
Current period deferrals	(13.9)	8.1	(21.7)	1.7
Amounts reclassified to net income (loss)	0	0	0	0
Cumulative effect of change in accounting standard				0
Other comprehensive income (loss), net of tax	(13.9)	8.1	(21.7)	1.7
Ending balance	(26.7)	(62.8)	(26.7)	(62.8)
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(54.9)	(127.1)	(68.4)	(71.9)
Current period deferrals	(12.9)	7.1	(16.1)	(39.5)
Amounts reclassified to net income (loss)	7	(1.5)	23.6	(6.4)
Cumulative effect of change in accounting standard				(3.7)
Other comprehensive income (loss), net of tax	(5.9)	5.6	7.5	(49.6)
Ending balance	$ (61)	$ (121.5)	$ (61)	$ (121.5)

Other (Income) Expense, Net - A

Other (Income) Expense, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Oct. 03, 2021	Sep. 27, 2020
Other Income And Expenses [Abstract]
Other income (expense), net	$ 2.6	$ 5.9	$ (50.8)	$ (61.1)
Gain (loss) on early extinguishment of debt	0	0	(50.3)	(12.6)
Foreign currency gain (loss), net	0.7	5.4		49.4
Unrealized foreign currency gain (loss), net	4.3	3.9	$ 38	$ 51.1
Fair value gains interest rate caps	$ 1.5	$ 0.5